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Zeki	 S.	 Crypt	 dysplasia	 in	 Barrett's	 oesophagus	 shows	 clonal	 identity	 between	









identify	 patients	 at	 high	 risk	 of	 cancer.	 Studies	 have	 proposed	 that	 BO	 is	 a	
monoclonal	 lesion,	 however	 recent	 work	 has	 shown	 that	 there	 are	 multiple	
independent	 clones	 present.	 Project	 1:	 Determines	 the	 evolution	 of	 polyclonal	
dysplasia	 through	 sequencing	 and	mapping	 clones	 onto	 tissue	 sections.	 I	 show	
that	 several	 cases	 are	polyclonal	 but	 in	 each	 case	 only	 one	 clone	progresses	 to	
cancer,	 suggesting	 oesophageal	 cancers	 are	 monoclonal	 outgrows	 from	
polyclonal	 Barrett’s	 dysplasia.	 Project	 2:	 Aims	 to	 understand	 the	 clonal	
relationship	between	cells	 in	glands	displaying	basal	 crypt	dysplasia-like	atypia	
(BCDA),	as	 it	 is	unclear	whether	 those	cells	 in	 the	upper	part	of	 the	gland	arise	
from	the	same	stem	cell	that	generates	the	gland	bases.	Glands	displaying	BCDA	
show	 a	 common	 mutation	 between	 the	 dysplastic	 base	 and	 non-dysplastic	
surface	 suggesting	 a	 common	 cell	 of	 origin.	 Project	 3:	 50%	 of	 patients	 who	
undergo	 oesophagectomy	 for	 OA	 develop	 post-oesophagectomy	 Barrett’s	 (neo-
BO)	within	3-5	years	possibly	due	 to	a	 field	effect,	wherein	pre-neoplastic	 cells	
remain	post-resection	 in	histologically	normal	areas	of	epithelium	predisposing	
the	patient	 to	cancer	recurrence.	 	Here	 I	show	that	no	genetic	 link	between	the	
neo-BO	and	the	cancer	is	present.	Immunohistochemical	analysis	shows	that	neo-
Barrett’s	glands	are	gastric	in	nature.	Project	4:	The	stem	cell	dynamics	and	clonal	
expansion	 rates	 of	 BO	 are	 unknown.	 Here	 I	 employed	 diversity	 analysis	 of	
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developed	 as	 a	 consequence	 of	 chronic	 exposure	 to	 gastro-oesophageal	 reflux	
disease	 (GORD)	 (Reid	 et	 al.,	 2015).	 Barrett’s	 is	 highly	 prevalent	 in	 populations	
who	suffer	from	chronic	GORD	and	seen	typically	in	the	overweight,	middle-aged	
Caucasian	 male	 (Wong	 and	 Fitzgerald,	 2005).	 Around	 5-10%	 of	 patients	 with	
GORD	 subsequently,	 develop	 Barrett’s	 metaplasia	 (Voutilainen	 et	 al.,	 2000,	
Westhoff	et	al.,	2005).	The	known	incidence	of	Barrett’s	 in	western	populations	
varies	 from	 0.5-2%	 (Powell	 and	 McConkey,	 1992)	 and	 prevalence	 varies	 from	




In	 a	 large	 population-based	 study,	 the	 incidence	 of	 malignant	 progression	 in	
males	 and	 females	 is	 low;	 0.28%	 and	 0.13%	 per	 year	 respectively	 (Bhat	 et	 al.,	
2011).	 Considering	 the	 number	 of	 Barrett’s	 patients	 diagnosed	 each	 year,	 this	
represents	a	significant	number	of	patients	who	will	develop	OA.	The	incidence	of	





164	 person-years)	 (Yousef	 et	 al.,	 2008).	 Furthermore,	 the	 incidence	 of	 OA	 has	
been	particularly	rising	 in	 the	UK;	 in	2013,	OA	was	diagnosed	 in	8,161	patients	
resulting	 in	 7,610	 deaths	 within	 1	 year	 of	 diagnosis	
(http://info.cancerresearchuk.org/cancerstats).	The	5-year	survival	rate	of	OA	is	
around	15%	(‘Oesophageal	cancer	survival	statistics”.	Cancer	Research	UK)	and,	













dysplasia	 (Barr	 et	 al.,	 1996).	 These	 observations	 suggest,	 there	 may	 be	
multipotent	 stem	 cells	 within	 Barrett’s,	 which	 have	 the	 capacity	 to	 regenerate	
squamous	 epithelium	 (Berenson	 et	 al.,	 1993).	 However,	 histology	 of	 these	
squamous	islands	indicates	they	may	originate	from	the	deep	submucosal	ducts	









gastric	 mucosal	 fold	 and	 (c)	 the	 lower	 end	 of	 the	 oesophageal	 squamous	
epithelium.	 (d)	 Occasionally	 there	 are	 areas	 of	 white	 squamous	 epithelium	
within	 Barrett’s	 segment	 called	 squamous	 islands,	 which	 may	 originate	 from	







mucin	 secreting	 goblet	 cells	 usually	 seen	 in	 the	 bowel	 (Sampliner	 et	 al.,	 1996,	
Going	et	al.,	2004).	However,	according	to	the	British	Society	of	Gastroenterology	
(BSG),	 BO	 is	 defined	 as	 “an	 endoscopically	 apparent	 area	 above	 the	
oesophagogastric	 junction	 that	 is	 suggestive	 of	 Barrett’s	which	 is	 supported	 by	
the	finding	of	columnar	lined	oesophagus	on	histology.	The	presence	of	areas	of	
intestinal	 metaplasia	 (IM),	 although	 often	 present,	 is	 not	 a	 requirement	 for	
diagnosis”.	 	Typically,	Barrett	glands	show	the	presence	of	both	intestinal	goblet	













There	 is	 some	 evidence	 that	 Barrett’s	 glands	 can	 evolve	 from	 a	 gastric	 to	 an	
intestinal	 phenotype	 (Going	 et	 al.,	 2004).	 Therefore	 Barrett’s	 glands	 display	
phenotypic	 heterogeneity	 and	 can	 be	 defined	 as	 (i)	 complete	 intestinal	
metaplasia	 (IM)	 consisting	of	 goblet	 cells	 and	Paneth	 cells	 (Chandrasoma	et	 al.,	
2010),	(ii)	incomplete	IM,	consisting	of	both	gastric	and	intestinal	differentiation	
and	 (iii)	 cardia-type	 epithelium	 consisting	 of	mucinous	 glands	without	 parietal	
cells	 or	 goblet	 cells	 (Chandrasoma	 et	 al.,	 2000).	 Barrett	 glands	 contain	 both	





upper	 zone	 of	 the	 gland	 mainly	 consists	 of	 columnar	 foveolar	 cells	 which	 are	
positive	 for	MUC5AC	 and	TFF1	 and	 goblet	 cells	 (expressing	MUC2),	 the	middle	
zone	or	neck	is	the	stem	cell	zone	and	the	basal	region	mainly	consists	of	mucous	
secreting	cells	which	are	positive	for	MUC6	and	TFF2	(Figure	3).	Recently,	Lavery	







Stem	 cells	 are	 long-lived	 cells,	 which	 have	 the	 capacity	 to	 self-renew	



























with	 self-renewal	 and	multi-lineage	 capacity	 (Barker	 et	 al.,	 2007,	Barker	 et	 al.,	
2009).	Lavery	et	al.,	(2014)	have	shown	by	in	situ	hybridization	that	LGR5	mRNA	
is	 expressed	 in	 the	 isthmus	 or	 neck	 region	 of	 the	 Barrett’s	 gland.	 A	 similar	
distribution	is	seen	in	gastric	pylorus	glands,	suggesting	a	common	architecture	
between	 Barrett	 and	 gastric	 glands.	 In	 the	 same	 study,	 Lavery	 and	 colleagues	
injected	patients,	who	were	scheduled	to	have	an	oesophagectomy	for	Barrett’s	
adenocarcinoma,	 with	 low	 level	 radiolabelled	 iododeoxyuridine	 (a	 thymidine	
analogue	 that	 is	 incorporated	 into	 proliferating	 cells)	 permitting	 analysis	 of	
cellular	migration	 over	 time	 (the	 time	 between	 injection	 and	 operation).	 They	




glands	 is	 most	 concentrated	 in	 the	 neck	 region	 (Nicholson	 et	 al.,	 2012).	




























Gastro-oesophageal	 reflux	 consisting	 of	 acid	 and	 bile	 leads	 to	 ulceration	 of	 the	
lower	 end	of	 the	oesophagus,	 lined	by	 the	normal	 squamous	 epithelium.	 In	 the	
majority	 of	 cases	 squamous	 epithelium	 regenerates,	 however	 in	 a	 small	
proportion	of	patients	with	chronic	GORD,	the	squamous	epithelium	is	replaced	
by	 columnar	metaplasia	 (Spechler,	 2002).	 Over	 the	 last	 few	 decades,	 the	most	
accepted	hypothesis	is	that	bile	and	acid	reflux	over	the	GOJ	stimulates	abnormal	
differentiation	of	stem	cells	present	in	the	basal	layers	of	squamous	epithelium	at	
the	 lower	end	of	oesophagus	resulting	 in	Barrett’s	metaplasia	 (Jankowski	et	al.,	
1999,	Seery,	2002).	Furthermore,	during	the	17th	week	of	gestation	the	ciliated	
columnar	 lined	oesophagus	 is	replaced	by	squamous	epithelium	and	some	have	





between	 squamous	 and	 columnar	 epithelium	 which	 displays	 ultrastructural	
features	 of	 both	 squamous	 epithelium	 at	 the	 base	 and	 columnar	 epithelium	
superficially	 under	 certain	 conditions	 (Riddell,	 2005)	 including	 Barrett’s,	 in	
which	 it	 is	 strongly	 associated	with	 goblet	 cell	metaplasia	 (Shields	 et	 al.,	 2001,	
Upton	 et	 al.,	 2006).	MLE	 has	 been	 shown	 to	 be	 a	 histological	marker	 of	 GORD	
(Glickman	et	al.,	2009).	Glickman	et	al.,	have	shown	that	MLE	expresses	mucins	
such	 as	 sialomucin	 (in	 100%	 of	 cases),	 neutral	 mucin	 (88%)	 and	 sulfomucin	
(71%)	 along	 with	 expression	 of	 specific	 cytokeratins	 (CK13	 and	 19	 in	 basal	
squamous	 epithelium	 and	 CK	 7,	 8/18,	 19	 and	 20	 in	 the	 superficial	 columnar	
	
25	
epithelium),	 these	 characteristics	 are	 similar	 to	 the	 cytokeratin	 profile	 of	
Barrett’s.	 In	 a	 single	 patient	 they	 observed	 a	mucosal	 gland	 duct	 in	 continuity	
with	 MLE	 suggesting	 a	 common	 cell	 of	 origin	 and	 that	 MLE	 maybe	 an	 early	
transitioning	stage	to	Barrett’s,	but	this	 is	unconfirmed	and	could	be	artefactual	
(Glickman	 et	 al.,	 2009).	 In	 a	 recent	 prospective	 Central	 European	 Multicenter	
(histoGERD	trial)	cross-sectional	study,	MLE	was	seen	either	within	or	adjacent	
to	 an	 oesophageal	 gland	duct	 in	 1	 in	 10	 individuals	 undergoing	OGD.	MLE	was	
seen	to	be	associated	with	increasing	age,	obesity,	hiatus	hernia,	oesophagitis	and	
Barrett’s	 (p=0.001,	0.026,	0.001,	0.002	and	0.001	respectively)	 indicating	GORD	




After	 endoscopic	 ablation	 therapy	 for	 Barrett’s,	 some	 areas	 of	 Barrett’s	 are	
replaced	by	squamous	epithelium	(Biddlestone	et	al.,	1998),	MLE	may	play	a	role	
in	 bringing	 this	 change	 in	 phenotype.	 However,	 regenerated	 squamous	
epithelium	does	not	exhibit	MLE.	MLE	is	most	commonly	seen	towards	the	area	
of	high	inflammation	(Shields	et	al.,	2001)	and	is	not	seen	along	the	entire	length	
of	 the	Barrett’s	segment	(Upton	et	al.,	2006),	 suggesting	 that	 inflammation	may	
not	 be	 the	 driving	 force	 behind	 the	 origin	 of	 MLE.	 It	 may	 well	 be	 that	 a	 high	
degree	 of	 inflammation	 at	 the	 squamocolumnar	 junction	 promotes	 the	
development	 of	MLE,	which	may	 transition	 into	 Barrett’s	 epithelium.	However,	





The	 submucosal	 gland	 is	 a	 tubule-acinar	 structure	 with	 stratified	 squamous	
epithelium	 lining	 the	 duct	 (Al	 Yassin	 and	 Toner,	 1977)	 (Figure	 5).	 There	 is	
evidence	suggesting	that	cells	lying	in	deep	submucosal	glands	or	ducts	could	be	
the	source	of	Barrett’s	(Badreddine	and	Wang,	2010,	Souza	et	al.,	2008).	Coad	et	
al.,	 (2005)	 carried	 out	 serial	 sections	 through	 46	 Barrett’s	 specimens,	 21	
specimens	displayed	oesophageal	gland	ducts	in	continuity	with	surface	Barrett’s	




study,	15/15	squamous	 islands	 in	Barrett’s	were	 found	to	be	 in	continuity	with	
the	 underlying	 oesophageal	 gland	 ducts,	 suggesting	 that	 they	 are	 arising	 from	
deep	 mucosal	 glands	 (Coad	 et	 al.,	 2005).	 It	 has	 also	 been	 shown	 that	 the	
submucosal	gland	duct	contains	clonal	patches	of	CCO-deficient	cells	(Nicholson	
et	al.,	2012)	and	therefore	maybe	a	potential	site	of	a	stem	cell	niche	(Fellous	et	
al.,	 2009a).	 Leedham	 et	 al.,	 have	 presented	 a	 case	 that	 showed	 an	 oesophageal	
gland	 duct	 sharing	 a	 common	 p16	 point	 mutation	 with	 an	 area	 of	 Barrett’s	
contiguous	to	the	duct	indicating	that	both	had	a	common	cell	of	origin.	The	same	
mutation	 was	 also	 seen	 in	 oesophageal	 gland	 acini	 (Leedham	 et	 al.,	 2008),	
suggesting	 a	 bi-directional	 spread	 of	 mutation	 similar	 to	 that	 observed	 in	 the	













Barrett’s	 lesions	 after	 acid	 suppression	 or	 ablation	 therapy	 (Biddlestone	 et	 al.,	
1998).	Sometimes	they	arise	spontaneously	(Sampliner	et	al.,	1988).	Biddlestone	
et	 al.,	 have	 shown	 that	 NSEs	 can	 be	 seen	 in	 continuity	 with	 the	 neck	 of	 the	
Barrett’s	gland	(Biddlestone	et	al.,	1998).	Paulson	et	al.,	have	shown	that	NSEs,	do	
not	typically	share	common	somatic	mutations	with	adjacent	Barrett’s	epithelium	
(19	 out	 of	 20	 patients).	 However	 in	 a	 single	 patient	 there	 was	 a	 clonal	




experiment.	 Leedham	 et	 al.,	 have	 identified	 Barrett’s	 epithelium	 in	 continuity	
with	 a	 squamous	 island	 and	 have	 shown	 that	 the	 squamous	 island	 wild	 type	
compared	to	the	adjacent	TP53	mutated	Barrett’s	epithelium,	suggesting	that	NSE	
originated	from	a	different	clone	to	the	adjacent	Barrett’s	epithelium	(Leedham	et	
al.,	 2008).	 The	 same	 criticism	 of	 not	 targeting	 sufficient	 numbers	 of	 genes	 can	
also	be	 levelled	at	 this	study,	 therefore	 the	relationship	of	NSE	with	Barrett’s	 is	
still	a	matter	of	debate.	
	
Recent	 observations	 have	 shown	 that	 sub-mucosal	 glands	 were	 more	
concentrated	 underneath	 NSE	 compared	 to	 the	 columnar-lined	 Barrett’s	
epithelium	 and	 that	 sub-mucosal	 glands	 are	 more	 concentrated	 at	 the	
squamocolumnar	 junctions	 compared	 to	 the	 columnar	 and	 squamous-lined	
oesophageal	epithelium.	These	observations	suggest	that	both	NSE	and	Barrett’s	




Another	 potential	 source	 of	 Barrett’s	 oesophagus	 is	 the	 migration	 of	 gastric	
glands	 into	 an	 area	 denuded	 by	 acid/bile	 reflux	 that	 undergo	 intestinal	
metaplasia	 (Bremner	 et	 al.,	 1970,	 Barrett,	 1950).	 However,	 the	 presence	 of	
goblet	 cells	 is	 not	 necessary	 for	 the	 diagnosis	 of	 Barrett’s	 (Riddell	 and	 Odze,	
2009).	 It	may	well	be	that	the	cardiac	mucosa	at	 the	squamocolumnar	 junction	






the	development	of	 columnar	 epithelium	at	 the	oesophago-gastric	 anastomotic	
junction	 (Lord	 et	 al.,	 2004,	 Oberg	 et	 al.,	 2002,	 Meyer	 et	 al.,	 1979).	 Columnar	
epithelium	 found	 at	 the	 anastomotic	 junction	 is	 similar	 to	 the	 cardiac-type	
epithelium	 and	 shows	 progression	 towards	 intestinal	 metaplasia	 (Lord	 et	 al.,	
2004).	 	 In	 a	 study	 looking	 at	 biopsy	 specimens	 at	 different	 levels	 of	 Barrett’s	
segment,	Going	et	al.,	have	shown	that	gastric	cardia-like	epithelium	 is	present	
throughout	the	length	of	the	Barrett’s	segment.	However,	it	was	observed	more	
frequently	 at	 the	 distal	 end	 of	 the	 Barrett’s	 segment.	 Gastric	 oxyntic-like	
epithelium	 was	 often	 found	 in	 the	 distal	 segment	 of	 Barrett’s.	 Lavery	 et	 al.,	
(2014)	 have	 shown	 that	 Barrett’s	 glands	 consisting	 of	 gastric	 (MUC5AC	 and	
MUC6)	 and	 intestinal	 (MUC2	and	MUC3)	 cell	 lineages	 are	 clonal.	The	 stem	cell	





response	 to	 inflammation	 secondary	 to	 acid	 reflux,	 Lgr5+	 gastric	 cardiac	
progenitor	 cells	 migrate	 into	 the	 oesophagus,	 suggesting	 that	 Barrett’s	 may	






An	 alternative	 hypothesis	 for	 the	 origins	 of	 Barrett’s	 is	 that	 a	 remaining	




self-renewal	 capacity	 results	 in	 loss	 or	 ulceration	 of	 stratified	 squamous	
epithelium	((Yang	et	al.,	1998),	(Yang	et	al.,	1999),	(Senoo	et	al.,	2007).	Recently	
Wang	et	al.,	have	shown	that	p63	knockout	mice	develope	intestinal	metaplasia	
similar	 to	Barrett’s	 (Wang	et	 al.,	 2011).	They	also	 tried	 to	 track	 its	 source	 and	
suggested	Car4+/CK7+	 (carbonic	anhydrase/cytokeratin	7)	 cells	present	at	 the	
squamocolumnar	junction	(SCJ)	are	the	source	of	origin	of	Barrett’s	metaplasia.	
Usually,	 these	 cells	 were	 undermined	 and	 replaced	 by	 p63	 expressing	 cells	












	Long-term	 follow-up	 of	 patients	 who	 were	 diagnosed	 with	 columnar-lined	
oesophagus	 (CLO)	 either	 with	 or	 without	 IM	 has	 shown	 that	 there	 is	 no	
significant	difference	in	the	rate	of	progression	to	dysplasia	or	OA	amongst	those	
two	 groups	 (Gatenby	 et	 al.,	 2008).	 Recent	 evidence	 suggests	 that	 goblet	 cells	
containing	complete	IM	carry	a	higher	risk	of	developing	OA	(Desai	et	al.,	2012),	
but	Chandrasoma	et	al.,	have	shown	that	CLO	without	evidence	of	goblet	cells	did	
not	 carry	 any	 risk	 of	 developing	 OA	 (Chandrasoma	 et	 al.,	 2012).	 However,	
recently,	 Lavery	 et	 al.,	 have	 shown	 that	 non-goblet	 containing	 metaplastic	




Barrett’s	 oesophagus	 progresses	 through	 different	 histological	 stages	 before	
progressing	to	OA,	such	as	(a)	Barrett’s	metaplasia	(b)	Barrett’s	dysplasia	which	
can	 be	 low-grade	 dysplasia	 (LGD)	 or	 high-grade	 dysplasia	 (HGD)	 and	 (c)	
oesophageal	adenocarcinoma	(Figure	6).	Dysplasia	can	be	defined	as	“neoplastic	
epithelium	 confined	 to	 the	 basement	 membrane	 which	 can	 give	 rise	 to	
intraepithelial	neoplasia”	 (Skinner	et	 al.,	 1983).	The	dysplastic	 cells	 in	Barrett’s	
show	 evidence	 of	 high	 nuclear	 to	 cytoplasmic	 ratio,	 cellular	 atypia	 and	nuclear	
hyperchromasia	without	 stratification	 (Skinner	 et	 al.,	 1983).	Barrett’s	 dysplasia	
can	 be	 histologically	 graded	 as	 low-grade	 and	 high-grade	 depending	 on	 the	
	
32	
























show	 prominent	 nuclei	 with	 an	 increase	 in	 the	 nuclear	 to	 cytoplasmic	 ratio.	
Indefinite	 for	 Dysplasia	 is	 the	 term	 used	 when	 the	 diagnosis	 of	 dysplasia	 is	
ambiguous.	 	 It	 means	 that	 there	 are	 some	 histological	 abnormalities	 seen	 but	
dysplasia	 can’t	 be	 ruled	 out.	 A	 study	 from	 Netherlands	 has	 shown	 that	 the	
incidence	 rate	of	HGD	or	OA	 in	patients	diagnosed	with	 indefinite	 for	dysplasia	
was	1.4	per	100	person-years,	suggesting	the	need	for	their	surveillance	(Kestens	
et	 al.,	 2014).	 In	 low-grade	 dysplasia,	 10-15%	 may	 progress	 to	 high-grade	
dysplasia	 and	 adenocarcinoma	 over	 2-5years	 (Heading	 et	 al.,	 2005–	 BGS	
guidelines	 2005,	 http://www.bsg.org.uk).	 The	 incidence	 of	 OA	 in	 LGD	 was	
reported	as	1.4%	per	year	versus	0.17%	in	patients	with	no	dysplasia	(p<0.001)	









multiple	 mutations	 in	 critical	 genes	 over	 a	 period	 of	 time	 (Nordling,	 1953).	
Subsequently,	 in	 1976,	 Nowell	 et	 al.	 proposed	 the	 “somatic	 mutation	 theory”.	
According	 to	 the	 somatic	 mutation	 theory	 of	 cancer	 development,	 mutations	
occur	 in	 long-lived,	dividing	cell	populations	 such	as	 stem	cells	and	accumulate	
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Barrett’s	 oesophagus	 is	 a	 risk	 factor	 for	 the	 development	 of	 oesophageal	





the	 acquisition	 of	multiple	 genetic	 alterations,	 such	 as	 chromosomal	 instability	
(Chaves	 et	 al.,	 2007),	 TP53	 mutations	 (Prevo	 et	 al.,	 1999),	 CDKN2A	 mutations	
(Paulson	et	al.,	2008),	loss	of	heterozygosity	(LOH)	of	TP53	and	CDKN2A,	 loss	of	
p16	via	methylation	and	aneuploidy,	suggesting	that	clonal	evolution	during	the	
MDC	 sequence	 seems	 to	 follow	 a	 more	 complex	 pathway	 rather	 than	 a	 linear	
pathway.		
	




However,	 it	 is	 important	to	 identify	the	extent	of	 identical	mutation,	which	may	
be	 present	 in	 pre-dysplastic	 Barrett’s	 patients	 who	 do	 not	 progress	 to	 OA.	 A	





Barrett's,	whereas	TP53	 and	SMAD4	mutations	were	 seen	mainly	 in	 high-grade	
dysplasia	 and	 OA	 respectively	 (Weaver	 et	 al.,	 2014).	 However,	 Stachler	 et	 al.,	
(2015),	 using	 similar	 techniques	 demonstrated	 that	 TP53	 mutations	 were	
frequent	 in	 non-dysplastic	 Barrett’s	 (Stachler	 et	 al.,	 2015).	 These	 observations	
suggest,	 mutations	 identified	 in	 early	 non-dysplastic	 Barrett's	 can	 be	 used	 to	
predict	 patients	 who	 are	 at	 risk	 of	 progressing	 to	 OA.	 Interestingly,	 some	
mutations	found	in	pre-dysplastic	Barrett's	were	in	cancer-associated	genes	such	
as	 ARID1A	 and	 SMARCA4,	 suggesting	 that	 even	 pre-dysplastic	 Barrett's	 is	
characterised	by	 the	presence	of	 a	 complex	 genetically	mutated	 landscape.	The	
importance	of	these	genes	in	the	early	stages	of	MDC	is	unknown.	However,	these	










Maley	 et	 al.,	 have	 shown	 that	 clonal	 size	 consisting	of	TP53	 LOH	or	 aneuploidy	
carries	a	higher	risk	of	progression	to	OA	compared	to	CDKN2A	clone	size	(Maley	





different	 tumours	 had	 more	 than	 one	 clone	 and	 have	 suggested	 that	 tumours	
with	more	than	four	clones	within	a	sample	had	increased	mortality	risk.	These	




with	 significant	 polygenic	 overlap	 between	 BO	 and	 OA,	 suggesting	 that	 shared	
multiple	genetic	alterations	are	involved	in	the	progression	of	BO	to	OA	(Ek	et	al.,	
2013).	Similar	genetic	diversity	was	seen	in	a	case-cohort	follow-up	study	by	Li	et	
al.,	 SNP	arrays	 technique	was	used	 to	 investigate	 genetic	 alteration	 in	Barrett's	
patients	who	progressed	to	OA	(progressors)	and	patients	who	did	not	progress	
to	OA	(non-progressors).	They	have	shown	that	the	genomes	in	non-progressors	
remained	 stable	 and	 showed	 very	 little	 genetic	 diversity	 such	 as,	 genomic	
deletions,	 CDKN2A	 loss/LOH),	 whereas	 progressors	 showed	 significant	 genetic	
diversity	 such	 as	 chromosomal	 alterations	 in	 the	 form	 of	 gains/losses	 and	
genome	doublings	up	to	48	months	prior	to	the	development	of	cancer	(Li	et	al.,	
2014).	 Recently,	 a	 large	 population-based	 study	 using	 fluorescence	 in	 situ	
hybridization	 have	 also	 suggested	 that	 identifying	 genetic	 diversity	 within	 a	




high	 genetic	 diversity	 identified	 by	 an	 abnormal	 marker	 count	 had	 a	 8.7-fold	













that	 OA	 occurs	 as	 a	 consequence	 of	 change	 in	 copy	 number	 rather	 than	 a	
stepwise	accumulation	of	gene	alterations	(Stachler	et	al.,	2015).		However,	it	is	




et	 al.,	 2012).	 Gerlinger	 et	 al.,	 have	 used	 whole	 exome	 multi-region	 spatial	




al.,	2012).	 	Genomic	analysis	of	a	biopsy	sample	 from	a	 tumour	may	not	detect	











whole-genome	 sequencing	 to	 analyse	 paired	 samples	 taken	 at	 the	 same	 time	
from	 OA	 and	 the	 adjacent	 Barrett's.	 The	 average	 number	 of	 single	 nucleotide	
variants	 (SNVs)	 in	 Barrett's	 was	 much	 higher	 (6.7/Mb)	 compared	 to	 other	
cancers,	 such	as	 colorectal,	 breast,	 liver	and	multiple	myelomas	 (5.9	SNVs/Mb,	
1.1	 SNVs/Mb,	 3.6	 SNVs/Mb	 and	 2.9	 SNVs/Mb	 respectively).	 There	was	 a	 20%	
overlap	between	SNVs	in	Barrett's	and	OA	and	TP53	genomic	mutations	were	the	
most	common	recurrent	mutations	was	seen	in	almost	82%	of	OA	compared	to	
39%	 in	 Barrett's	 metaplasia.	 They	 also	 found	 that	 TP53	mutations	 found	 in	
adjacent	Barret's	mucosa	were	not	found	in	paired	samples	of	OA.	EYS,	ARIDIA	
and	ABCB1,	which	were	previously	reported	as	driver	genes	for	OA.	The	genetic	
heterogeneity	 seen	 within	 Barrett's	 tissue	 suggests	 polyclonality	 and	
interestingly	 very	 little	 genetic	 commonality	 between	 Barrett's	 and	 OA	 (Ross-
Innes	 et	 al.,	 2015).	 To	 further	 investigate	 the	 genetic	 landscape	 and	 genetic	
diversity,	 they	 sequenced	 samples	 from	a	 single	 patient	who	presented	with	 a	
10cm	 Barrett’s	 segment	 over	 a	 period	 of	 3	 years	 and	 had	 undergone	 five	
endoscopies	with	 78	 biopsy	 samples.	 This	 patient	was	 diagnosed	with	 various	
stages	 of	 Barrett’s	metaplasia,	 dysplasia	 and	 adenocarcinoma.	 In	 his	 follow-up	
specimens,	 six	 distinct	 clonal	 mutations	 were	 identified	 in	 the	 non-dysplastic	
Barrett's,	 of	 which	 four	 clones	 progressed	 to	 LGD,	 and	 three	 clones	 were	
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identified	 in	 HGD.	 Only	 four	 clones	 spread	 across	 the	 whole	 length	 of	 the	
Barrett's	 segment.	 These	 data	 support	 the	 polyclonal	 evolution	 model	 in	
Barrett's	 proposed	 by	 Leedham	 et	 al.,	 (2008).	 Interestingly,	 there	 were	 three	
common	 mutations	 (non-coding)	 present	 in	 all	 Barrett's	 samples	 supporting	
common	 ancestor	 model	 from	 Reid	 et	 al.,	 group	 (Maley	 et	 al.,	 2004b)	 and	
presence	 of	 multiple	 clones	 of	 which	 two	 clones	 were	 not	 able	 to	 selectively	
sweep	 across	 the	whole	 length	 of	 Barrett's	 segment	 supporting	 the	 polyclonal	
model	 of	 clonal	 evolution	 proposed	 by	 Leedham	 et	 al.,	 (2008).	 These	
observations	suggest	genetic	heterogeneity	 in	Barrett's	oesophagus,	which	was	







Determining	 the	 clonal	 architecture	of	 an	epithelial	unit	 (of	which	 the	Barrett’s	
gland	can	be	considered	as	one)	and	comparing	 it	with	other	units	 in	 the	same	
tissue	 allows	 for	 analysis	 of	 the	 evolution	 of	 premalignant	 disease	 to	 cancer.	
Clonal	 populations	 are	 groups	 of	 cells	 arising	 from	 a	 single	 progenitor.	 A	
mutation	 that	 gets	 passed	 onto	 a	 cell's	 progeny	 can	 be	 detected	 and	 used	 to	
lineage	 trace	 its	 ancestry,	which	 helps	 to	 distinguish	 those	 cells	 that	 are	 clonal	
from	 other	 unrelated	 cells.	 Various	 techniques	 have	 been	 used	 to	 assess	 tissue	






Identification	 of	 genetic	 alterations,	 such	 as	 genomic	 or	 mitochondrial	 point	
mutation	 can	 be	 used	 as	 markers	 of	 clonality:	 the	 likelihood	 that	 two	 cells	
sharing	 the	 same	 mutation	 originating	 from	 independent	 progenitor	 cells	 are	
low.	 	Regardless	if	such	common	mutations	affect	amino	acid	coding	or	protein	
function	 or	 not,	 their	 strength	 as	 clonal	 markers	 depends	 on	 the	 variation	 of	
mutations	within	each	gene	in	the	population.	 In	this	thesis	I	have	used	Sanger	






Mitochondria	are	organelles	 in	 the	 cell	 cytoplasm	whose	 function	 is	 to	produce	
energy	 via	 the	 production	 of	 adenosine	 triphosphate-ATP.	 Mitochondrial	 DNA	
(mtDNA)	is	double-stranded,	16,600	base	pairs	in	size	and	encodes	13	proteins,	2	
trRNAs	 and	 22	 tRNAs	 (Taanman,	 1999).	 MtDNA	 is	 susceptible	 to	 somatic	




for	 deficiency	 of	 cytochrome	 c	 oxidase	 (CCO)	 which	 has	 been	 shown	 to	 be	
frequently	mutated	in	aged	human	cells	(Fellous	et	al.,	2009b).	Tracing	common	
mutations	 in	 CCO-deficient	 cells	 permits	 clonal	 analysis	 in	 tissues.	 MtDNA	




al.,	 2003)	 and	 colonic	 adenomas	 (Humphries	 et	 al.,	 2013).	 Studies	 in	 Barrett’s,	





DNA	 Microsatellites	 (MS)	 are	 simple	 sequence	 repeats	 consisting	 of	 2-5	 base	






nucleotide	 repeats	 varies	 within	 a	 population	 but	 is	 inherited.	 LOH	 has	 been	




amplified	 microsatellite	 markers,	 from	 metaplasia-dysplasia-carcinoma	 MDC	
areas	can	be	compared	with	non-epithelial	tissue	from	the	same	patient	(which	
acts	 as	 a	 control	 or	 constitutional	DNA).	The	healthy	 tissue	usually	 shows	 two	
allelic	peaks;	rarely	we	may	see	only	one	allelic	peak	indicating	that	the	sample	is	
non-informative	 (and	 we	 are	 unable	 to	 detect	 loss	 of	 one	 of	 the	 alleles)	 and	
therefore	 this	 cannot	 be	 used	 to	 compare	 with	 the	 tumour	 samples.	 LOH	 is	
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considered	 to	 be	 present	 if	 the	 area	 under	 one	 allelic	 peak	 was	 less	 than	 0.5	


























































by	 (Braakhuis	 et	 al.,	 2003),	 suggesting	 that	 carcinomas	 and	 their	 surrounding	
histologically	 normal	 epithelium	 share	 a	 common	 genetic	 alteration,	 such	 as,	 a	




clonally	 related	cells	with	a	 susceptibility	 to	 cancer	 formation	 (Braakhuis	et	 al.,	
2003)	This	carries	an	important	clinical	implication:	apparently	morphologically	
normal	 epithelium	 surrounding	 a	 resection	 margin	 may	 possess	 genetic	
abnormalities	that	when	left	in	situ,	may	result	in	the	recurrence	of	cancer.	
	




that	 the	 same	 somactic	 TP53	 mutation	 identified	 from	 the	 cancer	 occurred	 in	
multiple	 sites	 in	 both	 lungs	 showing	 squamous	metaplasia.	 A	 single	 clone	 had	
therefore	spread	across	a	long	distance,	suggesting	field	cancerization	in	the	lung	
(Franklin	et	al.,	1997).	In	the	colon;	Mutations	in	TP53	and	KRAS	found	in	colitis-
associated	 cancer	 were	 also	 found	 in	 surrounding	 non-dysplastic	 crypts,	
suggesting	 clonality	 and	 field	 concretization	 (Leedham	 et	 al.,	 2009).	 Pancreas;	
Identical	KRAS	mutation	was	seen	in	intraductal	papillary	mucinous	tumour	and	
the	surrounding	normal	tissue	(Kitago	et	al.,	2004),	skin	(Hafner	et	al.,	2010)	and	














primary	 mechanism	 by	 which	 adenomas	 expand	 in	 familial	 adenomatous	
polyposis	 (FAP)	 (Wasan	 et	 al.,	 1998).	 Gland	 fission	 also	 appears	 to	 be	 the	
primary	mechanism	 by	 which	 clones	 spread	 in	 the	 stomach	 (McDonald	 et	 al.,	
2008)	and	colon	(Greaves	et	al.,	2006).	In	Barrett’s,	Nicholson	et	al.,	have	shown	
large	patches	of	CCO-deficient	glands	sharing	 the	same	non-pathogenic	mtDNA	






Stem	 cells	 present	 at	 the	 base	 of	 a	 crypt	 (A)	 acquire	 somatic	 mutation	 (B).	
Mutated	 cells	 clonally	 expand	 through	 the	 entire	 crypt	 leading	 to	 monoclonal	





can	 be	 present	 throughout	 large	 segments	 (17cm)	 of	 Barrett’s	 oesophagus,	
suggesting	 that	 Barrett’s	 is	 the	 product	 of	 field	 cancerization,	 and	 these	 clones	
can	be	detected	6	years	before	the	development	of	cancer	(Barrett	et	al.,	1999).	
Further	studies	have	shown	genetic	alterations	in	CDKN2A	and	TP53	are	present	
in	 premalignant	 Barrett’s,	 years	 before	 the	 development	 of	 OA	 (Galipeau	 et	 al.,	
1999,	Maley	 et	 al.,	 2004b),	 suggesting	 that	Barrett’s	metaplasia	be	defined	 as	 a	
field	 cancerization.	 It	 has	 been	 shown	 that	 histological	 clear	margins	 following	
oesophagectomy	for	BO-related	OA	have	a	better	prognosis	(Dexter	et	al.,	2001).	
However,	 Kim	 et	 al.,	 2006,	 have	 shown	 that	 KRAS	 mutation	 seen	 in	 53%	 of	
histologically	 clear	 resection	 margins	 following	 pancreatectomy	 for	 pancreatic	
adenocarcinoma	had	a	poorer	prognosis	compared	to	KRAS	-ve	resection	margins	
(Kim	 et	 al.,	 2006a).	 This	 raises	 the	 possibility	 that	 neo-Barrett’s	 following	
oesophagectomy	could	develop	as	a	consequence	of	field	cancerization	effect.	At	
least	 10%	 of	 gastric	 carcinoma	 patients	 have	 synchronous	 or	 metachronous	
tumours	(Marrano	et	al.,	1987),	however,	 the	clonal	relationship	between	these	
cancers	was	not	established.	These	studies	 suggest	 that	 field	 cancerization	may	
be	 the	 underlying	 mechanism	 of	 further	 cancer	 development,	 and,	 therefore,	
synchronous	 tumours	 should	 have	 a	 founder	 mutation	 (Galipeau	 et	 al.,	 1999,	
Maley	 et	 al.,	 2004b).	 Leedham	 et	 al.,	 have	 shown,	 in	 ulcerative	 colitis,	 that	
adenocarcinoma	and	the	adjacent	non-dysplastic	 tissue	share	 the	same	TP53	or	
KRAS	 mutation,	 suggesting	 field	 cancerization	 in	 the	 preneoplastic	 tissue	
(Leedham	et	 al.,	 2009).	Recent	work	 in	Crohn’s	disease	by	Galandiuk	et	 al.,	 has	





can	 encompass	 extensive	 areas	 of	 the	 colon	 and	 also	 suggests	 some	 degree	 of	
plasticity	 in	 the	 colon	 and	 small	 bowel.	 Salk	 et	 al.,	 have	 suggested	 that	
identification	of	pre-tumour	clonal	expansion	in	non-dysplastic	ulcerative	colitis	
which	could	be	used	as	a	guide	to	identify	patients	at	risk	of	developing	ulcerative	
colitis-associated	 carcinoma	 (Salk	 et	 al.,	 2009).	 These	 clones	 appear	 before	 the	
development	of	carcinoma.	Hence,	characterization	of	pre-tumour	clones	in	that	











specimens	 are	 an	 excellent	means	 to	 study	 the	 genesis	 of	Barrett’s	 oesophagus	
and	 these	 patients	 undergo	 an	 increased	 frequency	 of	 surveillance.	 This	
serendipitously	provides	us	with	a	model	that	is	currently	lacking	in	Barrett’.	It	is	
difficult	 to	observe	early	Barrett’s	 in	 the	general	population	due	to	the	 fact	 that	
symptoms	may	not	be	present	or	are	ignored	by	patients.	Neo-Barrett’s	gives	us	








Dresner	 et	 al.,	 have	 shown	 that	 post-oesophagectomy	 patients	 are	 exposed	 to	
increase	 acid	 reflux,	 35%	 (14	 out	 of	 40)	 of	 patients	 had	 developed	 grade	 I-III	
oesophagitis	 (Dresner	 et	 al.,	 2003).	 In	 a	 recent	 study;	 151	 patients	 with	 OA	
underwent	oesophagectomy,	98	out	of	151	underwent	fundoplication	(wrapping	
of	 the	 remnant	 stomach	 around	 the	 anastomosis,	 which	 mimics	 lower	
oesophageal	sphincter	and	reduces	acid	reflux)	and	53	patients	did	not	have	this	
procedure.	 Post-op	 follow-up	 endoscopy	 revealed	 neo-Barrett’s	 in	 6%	 of	
fundoplication	 group	 compared	 to	 18%	 in	 patients	 without	 fundoplication,	
suggesting	the	role	of	acid	reflux	in	the	development	of	neo-Barrett’s	and	lower	






pink	 mucosa	 (similar	 to	 Barrett’s	 oesophagus)	 above	 the	 gastro-oesophageal	
anastomotic	 line	 (Figure	 10).	 Neo-Barrett’s	 can	 present	 in	 a	 circumferential	
manner	 or	 a	 tongue-like	 projection	 at	 the	 gastro-oesophageal	 anastomotic	













Dresner	 et	 al.,	 in	 their	 study,	 have	 shown	 that	 48%	 of	 patients	 developed	
columnar	 metaplasia	 post-oesophagectomy,	 approximately	 half	 of	 which	
displayed	gastric	cardia-type	epithelium	and	the	remainder	with	IM.	Upon	follow	
up	those	that	showed	cardia-type	epithelium	were	found	to	develop	IM	at	a	later	
date,	 suggesting	 that	 gastric	 cardiac	 type	 epithelium	 appears	 first	 following	
oesophagectomy	 (Dresner	 et	 al.,	 2003).	 These	 observations	 have	 also	 been	
confirmed	by	Lord	et	al.,	who	has	shown	that	the	oesophageal	epithelium	above	
the	 anastomosis	 changes	 from	 normal	 squamous	 epithelium	 to	 cardiac	 type	
followed	 by	 intestinal	 metaplasia	 (Lord	 et	 al.,	 2004).	 The	 columnar	mucosa	 of	
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neo-Barrett’s	 stained	 for	 CK7/20	 and	 DAS-1	 showed	 patterns	 similar	 to	 the	
control	group	who	had	Barrett’s.	The	cardiac	mucosa	was	seen	to	develop	within	
1-2	 years	 followed	 by	 intestinal	 metaplasia	 in	 3-5	 years	 (Lord	 et	 al.,	 2004,	











from	 tissue	 sections.	 This	 limits	 us	 to	 temporal	 but	 not	 spatial	 analysis.	 The	
molecular	 clock	 theory	 suggests	 that	 the	 diversity	 between	 the	 genotypes	 or	
epigenomes	of	two	cell	types	reflects	the	time	since	their	common	ancestry;	the	
greater	the	number	of	replication	errors	the	greater	the	number	of	divisions	will	
have	 occurred	 and	 therefore	 is	 a	 measurement	 of	 time	 (Bromham	 and	 Penny,	
2003).	 Gene	 expression	 can	 be	 regulated	 by	 methylation	 of	 CpG	 sites	 in	 its	
promoter.	Areas	of	promoters	rich	in	CpG	sites	are	called	CpG	islands.	At	birth	all	






of	 cell	 divisions	 increases,	 the	methylation	 pattern	 between	 two	 daughter	 cells	




This	 project	 aims	 to	 use	 methylation	 patterns	 of	 CpG	 islands	 in	 the	 promoter	
region	 of	 non-expressed	 genes	 such	 as	 CSX	 (cardiac-specific	 homeobox)	 and	
MYOD	(member	of	basic-helix-loop-helix	family	of	proteins)	as	markers	of	clonal	
expansion.	 Since	 these	 genes	 are	 not	 expressed,	 there	 is	 no	 selection	 for	 a	
particular	methylation	signature.	Adjacent	glands	may	share	a	common	ancestry	
if	 their	parent	gland	has	divided	by	 fission.	 In	the	normal	human	colon	this	 is	a	
rare	 event	 (Graham	 et	 al.,	 2011a),	 though	 in	 conditions	 of	 inflammation	 crypt	
fission	 is	 increased	 (Cheng	 et	 al.,	 1986)	&	 (Wong	 et	 al.,	 2002).	 Estimating	 the	
fission	rate	requires	a	marker	of	clonal	expansion	that	changes	over	time	at	a	low	
but	measurable	 rate.	This	would	allow	us	 to	estimate	 the	growth	and	 stem	cell	
dynamics	 within	 glands	 that	 are	 related.	 Methylation	 patterns	 become	 diverse	
with	ageing	in	mitotic	tissues	such	as	the	colon	(Yatabe	et	al.,	2001).	Since	mitotic	
errors	 can	mainly	 be	 accumulated	 in	 the	 long-term	 through	 stem	 cell	 lineages,	
their	methylation	 patterns	 record	 ancestry	 and	 this	 can	 be	 used	 to	 understand	
stem	cell	dynamics	(Shibata,	2009).		
	
Stem	 cell	 diversity	 can	 be	 explained	 by	 two	 different	 scenarios.	 The	 immortal	
stem	 cell	 scenario,	 where	 individual	 Barrett’s	 glands	 are	 maintained	 by	 a	
population	of	 immortal	 stem	cells	each	generating	 their	own	progeny	 therefore	
stem	cell	diversity	 remains	 the	same	over	 time	or	a	niche	scenario	where	stem	
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cells	 undergo	 random	 loss	 and	 replacement	 from	 the	niche	 creating	 a	 series	 of	





greater	period	of	 time	since	 fission.	Unrelated	glands	will	 show	no	similarity	 in	







11	 methylation	 tags	 sampled	 from	 two	 different	 Barrett’s	 glands.	 Each	 row	
represents	methylation	tags	 from	individual	cloned	PCR	products	derived	 from	
bisulfite	 treated	 DNA	 extracted	 from	 a	 single	 Barrett’s	 gland.	 Each	 column	











0 0 0 0 0
1 0 0 0 1
0 0 0 1 1
1 0 1 1 1
0 0 0 1 1
1 1 0 1 1
1 0 0 1 1
0 0 1 1 1
0 0 1 0 1
0 1 0 1 1
1 1 1 1 1
More diverse methylation 
patterns
0 0 0 0 1
0 0 0 0 1
0 0 0 1 1
0 0 0 1 1
0 0 0 1 1
0 0 1 1 1
0 0 1 1 1
0 0 1 1 1
0 0 1 1 1
0 0 1 1 1
0 0 1 1 1































Chapter-1:	 A	 total	 of	 36	 patient	 specimens	 (EMRs	 &	 oesophagectomies)	 were	




Chapter-2:	A	 total	 of	 25	patient	 oesophagectomy	 specimens	 from	patients	with	
neo-Barrett’s	were	initially	screened	for	CDKN2A	(p16),	TP53	and	KRAS.	
	
Chapter-3	 and	 Chapter-4:	 Paraffin-embedded	 and	 fresh	 frozen	 endoscopic	




Ethics:	 Multicentre	 Ethics	 approval	 was	 obtained	 from	 (i)	 National	 Research	
Ethics	 Service,	 Stanmore,	 London	 (11/LO/1613)	 and	 (ii)	 Oxfordshire	 Research	








Specimens	were	 initially	 screened	 for	 genomic	 DNA	mutations	 in	 genes,	which	
are	 known	 to	 be	mutated	 in	 Barrett’s	 adenocarcinoma,	 namely	CDKN2A	 (p16),	
TP53	and	KRAS.	The	areas	of	dysplasia/cancer	were	identified	on	a	haematoxylin	
and	 eosin-stained	 section	 and	 traced	 onto	 four	 serial	 dewaxed	 and	 unstained	












from	 the	 surrounding	 stroma.	 A	 serial	 haematoxylin	 and	 eosin	 stain	 were	
performed	 to	 act	 as	 a	 guide	 for	 microdissection.	 Individual	 glands	 were	 laser	
microdissected	using	a	P.A.L.M.	laser	capture	dissection	microscope	system	into	
0.5ml	 adhesive	 cap	 tubes	 (Zeiss,	 Munich,	 Germany).	 Each	 captured	 gland	 was	













14μl	 of	 Picopure	 proteinase	K	 solution	 (Applied	Biosystems,	 U.K)	 at	 65oC	 for	 a	
minimum	 period	 of	 3	 hours	 and	 then	 denatured	 at	 95oC	 for	 10	 minutes.	 In	
partially	 CCO-deficient	 glands,	 a	 single	 cell	 from	 CCO-deficient	 (blue)	 area	was	







reaction	 mixture	 containing	 0.4pmol	 of	 first	 round	 forward	 and	 reverse	 gene-
specific	 primers	 (Appendix,	 Table	 –	 6),	MgCl2	 (Qiagen,	 Crawley,	 UK),	 0.2mM	 of	
each	dNTP	(Life	Science,	Buckinghamshire,	U.K),	Q	solution	(Qiagen,	Crawley,	UK)	
and	1unit	of	Taq	polymerase	(Qiagen,	Crawley,	UK).	The	precise	concentrations	of	
MgCl2	 and	volumes	of	Q	 solution	 are	outlined	 in	Table	8).	 The	 first	 round	PCR	
was	 prepared	 in	 an	 Omni	 PCR	 UV	 hood	 (Bioquell,	 Berkshire,	 U.K)	 to	 reduce	
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contamination	 and	 then	 subjected	 to	 37	 cycles	 of	 denaturing,	 annealing	 and	
extension	 (Appendix,	 Table	 9).	 1μl	 of	 the	 first	 round	 PCR	 product	 was	 then	
subjected	 to	 a	 second	 round	 of	 PCR	 subjected	 to	 37	 cycles	 of	 denaturing,	
annealing	 and	 extension	 (Appendix,	 Table	 9).	 Details	 of	 individual	 primer	
reactions	 are	 again	 detailed	 in	 Appendix,	 Table	 9.	 To	 ensure	 successful	




The	 entire	 mitochondrial	 genome	 was	 amplified	 into	 nine	 2kb	 segments	 by	 a	
series	 of	 overlapping	 primers	 designed	 to	 amplify	 each	 segment.	 To	 achieve	
sufficient	quantities	of	DNA	to	sequence,	a	nested	PCR	protocol	was	applied	using	
36	 M13-tailed	 primers	 resulting	 in	 each	 2kb	 fragment	 split	 into	 four	 500bp	
fragments.	 	 Briefly,	 1μl	 of	 DNA	 extracted	 was	 added	 to	 a	 25μl	 PCR	 reaction	
mixture	 containing	 0.6μmol	 of	 first	 round	 forward	 and	 reverse	 gene-specific	
primers	(Appendix,	Table	12	and	13),	1mM	MgCl2	(Qiagen,	Crawley,	UK),	0.2mM	
of	 each	 dNTP	 (Life	 Science,	 Buckinghamshire,	 U.K),	 and	 1.75units	 of	 AmpliTaq	
Gold	polymerase	(Applied	Biosystems,	U.K).	The	first	round	PCR	was	prepared	in	
an	 Omni	 PCR	 UV	 hood	 (Bioquell,	 Berkshire,	 U.K)	 to	 reduce	 contamination	 and	











The	 purification	 of	 PCR	 products	 was	 performed,	 by	 adding	 2μl	 of	 ExoSAP-IT	
(USB	Corporation,	Cleveland,	OH)	to	5μl	of	second	round	PCR	product	and	run	on	







PCR	 products	 were	 subjected	 to	 Sanger	 sequencing.	 Sequencing	 reaction	
conditions	are	shown	in	Appendix,	Table	10.	Each	sequencing	reaction	contained	
4μl	of	diluted	exosap-treated	PCR	product,	 1μl	of	primer	 (forward	or	 reverse),	
5μl	of	distilled	water,	and	10μl	of	Big	Dye	Terminator	(Applied	Biosystems,	U.K).	
Genomic	 primers	 for	TP53,	 CDNK2A	 and	KRAS	 are	 described	 in	 the	 appendix.	
Each	 sequencing	 reaction	 was	 run	 on	 an	 ABI	 3100	 DNA	 sequencer	 (Applied	
Biosystems,	 Foster	 City,	 California,	 USA).	 The	 sequences	 obtained	 were	
compared	 with	 the	 Catalogue	 of	 Somatic	 Mutations	 in	 Cancer	








15)	 permitting	 universal	 sequencing.	 Each	 sequence	 output	 was	 compared	





To	 understand	 the	 clonal	 architecture	 and	 the	 spatial	 distribution	 of	 different	
clones	 in	 each	 EMR	 and	 oesophagectomy	 specimen,	 topographical	 maps	
indicating	the	mutational	status	or	LOH	of	individual	laser	captured	glands	with	







D9S43,	 D9S171,	 D9S1752),	 17p	 (TP53	 -	 D17S1832,	 D17S1176,	 D17S1678,	
D17S1881),	 5q	 (APC	 –	 D5S346,	 D5S2001,	 D5S489),	 3p	 (FHIT	 –	 D3S1300),	 and	
18q	 (SMAD4	 –	 D18S58,	 D18S474F)	 were	 selected	 using	 the	 University	 of	
California,	Santa	Cruz	database	(http://genome.ucsc.edu).	The	microsatellite	loci	





HEX	 (hexachloro-6-carboxyfluorescin)	 fluorescent	 marker.	 The	 amplified	
microsatellite	 markers	 from	 metaplastic,	 dysplastic	 and	 cancerous	 areas	 were	
compared	with	constitutional	DNA	(muscle)	from	the	same	patient	and	analysed	
on	 an	 ABI	 3100	 Genetic	 analyser	 (Applied	 Biosystems).	 Results	 were	 analysed	
using	 GeneMapper	 software	 (Applied	 Biosystems).	 For	 each	 marker,	 loss	 of	
heterozygosity	was	 considered	 to	 be	 present	 if	 the	 area	 under	 one	 allelic	 peak	
was	 less	 than	 0.5	 times	 or	more	 than	 two	 times	 the	 area	 of	 the	 corresponding	
allele	 in	 the	 constitutional	 DNA.	 LOH	 of	 a	 single	 microsatellite	 marker	 is	 not	







Frozen	 sections	 were	 air-dried	 for	 45	 minutes	 and	 dual	 CCO	 and	 succinate	
dehydrogenase	 (SDH,	 a	 nuclear-encoded	 mitochondrial-active	 enzyme)	
histochemistry	 was	 performed.	 Sections	 were	 first	 incubated	 in	 CCO	 medium	
(100mmol/litre	 cytochrome	 c,	 20mg/ml	 catalase	 and	 4	 mmol/litre	
diaminobenzidine(DAB)	tetrahydrochloride	in	0.2	mol/litre	phosphate	buffer,	pH	
7.0,	all	sourced	from	Sigma-Aldrich,	Poole,	UK)	for	45-60	minutes	at	37°C.	Crypts	
with	 normal	 CCO	 activity	 stain	 brown,	 sections	were	washed	 three	 times	with	





sodium	azide,	 all	 sourced	 from	Sigma-Aldrich,	 Poole,	UK)	 for	 a	maximum	of	 45	
minutes	 at	 37°C,	 or	 until	 an	 intense	 blue	 stain	 had	 developed	 in	 CCO-deficient	
cells.	Sections	were	washed	in	PBS	for	3x5	minutes	and	dehydrated	in	a	graded	
ethanol	series	(70%,	90%,	100%,	100%).	 If	 tissue	was	 for	LCMD,	sections	were	
further	 air-dried	 for	 1	 hour	 before	 being	 used	 or	 stored	 at	 -80°C.	 	 Single	 CCO-









EpiTect	 Plus	 Bisulphite	 kits	 (Qiagen,	 UK)	 were	 used	 for	 bisulphite-treating	
extracted	 DNA.	 When	 sodium	 bisulphite	 is	 applied	 to	 DNA,	 unmethylated	
cytosines	 are	 converted	 to	 uracils	 yet	methylated	 cytosines	 remain	 unchanged.	
Each	 bisulphite	 reaction	 of	 140μl	 consists	 of	 DNA	 (1ng-2ng),	 RNase-free	water	
(extracted	 DNA	 +	 RNase-free	 water	 must	 total	 20μl),	 Bisulphite	 mix	 dissolved	










Barrett’s	 glands	were	 laser-captured	microdissected	 (1)	 followed	by	bisulphite	
treatment	 of	 extracted	 DNA	 (2),	 where-in	 unmethylated	 cytosines	 were	
converted	 to	 uracil	 (Thymidine).	 Followed	by	TA-cloning	 (3),	wherein	 the	Taq	
DNA	 polymerase	 adds	 a	 3'-terminal	 “A”	 overhang	 on	 either	 end	 of	 the	 PCR	
product,	 which	 helps	 in	 cloning	 of	 the	 PCR	 product	 and	 Vector	 ligation	 (4).	
Competent	 JM109	 cells	 (Promega,	 UK)	 were	 used	 for	 transformation	 of	 the	



























5) Transformation of 
competent cells
1) Laser capture 
microdissection 
and DNA extraction
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to	DNA	 fragmentation,	hence	a	 two-round	nested	PCR	was	used	 to	 increase	 the	
DNA	yield.	CpG	islands	of	non-expressed	genes	MYOD1	(Myoblast	determination	
protein	 1	 on	 chromosome	 11p)	 and	 CSX	 (Cardiac-specific	 homeobox	 on	
chromosome	 5q)	 were	 amplified.	 Primers	 were	 designed	 using	 the	 Primer	 3	
website	 (MIT,	 Cambridge,	 Massachusetts,	 USA)	 (for	 primer	 sequences	 see	
Appendices,	Table	15	and	16).	To	ensure	successful	amplification,	2nd	round	PCR	










of	 the	PCR	product,	which	permits	 cloning	of	 the	PCR	product.	The	vector	also	




Each	 10μl	 ligation	 reaction	 consisted	 of	 2μl	 PCR	 product,	 5μl	 Rapid	 Ligation	
Buffer	(Promega,	UK),	1μl	vector,	1μl	T4	DNA	Ligase	and	1μl	nuclease-free	water.	




Competent	 JM109	 cells	 (>1	 x	 108cfu/	 mg	 DNA,	 Promega,	 UK)	 were	 used	 for	




SOC	 medium	 was	 added	 at	 room	 temperature	 and	 Incubated	 at	 37oC	 for	 90	
minutes	 on	 a	 shaker	 (225rpm).	 100ml	 of	 transformation	 product	 was	 plated	
onto	 LB-agar	 plate	 containing	 ampicillin,	 X-galactose	 and	 Isopropyl	 β-D-1-
thiogalactopyranoside	 (IPTG)	 (Sigma,	 UK).	 Plates	 were	 incubated	 overnight	 at	
37oC.	Cloning	of	PCR	products	into	the	vector	interrupts	the	coding	sequence	of	















The	pattern	of	methylated	 and	unmethylated	 sites	 in	 non-expressed	 genes	was	
analysed	according	 to	Yatabe	and	colleagues	methodology	(Yatabe	et	al.,	2001).	
The	methylation	patterns	observed	in	one	CpG	island/at	a	single	locus	is	called	a	
tag.	 To	 analyse	 methylation	 patterns	 within	 each	 gland/clone	 and	 to	 compare	















It	 is	 the	 average	 difference	 between	 the	 number	 of	 methylation	 tags	 within	 a	
gland/clone,	which	measures	 the	 epigenetic	diversity	within	 a	 gland/clone.	 For	


























tags	 and	percentage	methylation	between	 individual	 patients	 specimen	 for	CSX	
and	MYOD	gene	(Chapter	6).		
4.	 Spearman	 correlation:	 To	 calculate	 the	 correlation	 between	 the	 percent	
methylation	and	patient	age	(Chapter	6).	
	
To analyse methylation patterns within each crypt/clone and to compare them with the 
adjacent crypt/clone the following statistical parameters were used.  
Where k =1,… M CpG sites, N is number of sequences analysed within that crypt at 
locus l (CSX or MYOD) in the tag j and M is number of CpG sites at locus l. 
Sljk = 0 denoted un-methylated site and Sljk = 0 denoted methylated site. 
 
Intra-crypt or Intra-clone diversity (A): 
 
  
Inter-crypt or Inter-clone diversity (I): 
 
Sljk and Cljk represents methylation tags, whereas, N1 and N2 represents number of 








and	 used	 to	 study	 p53,	 Ki67,	MUC2,	MUC5AC,	MUC6,	 TFF1	 and	 TFF2	 staining.	
Sections	 were	 dewaxed,	 rehydrated	 using	 decreasing	 dilutions	 of	 alcohol	 and	
endogenous	peroxidase	was	blocked	using	3%	hydrogen	peroxide	 in	methanol	
for	 10	 minutes.	 Antigen	 retrieval	 was	 achieved	 by	 microwaving	 slides	 in	 1M	
citrate	buffer	(pH6.0)	for	10	minutes.	Slides	were	incubated	in	rabbit	serum	for	
15	minutes,	 followed	by	 incubation	 in	a	primary	antibody	1	hour,	 then	washed	
3x5	 mins	 in	 PBS.	 The	 sections	 were	 then	 incubated	 with	 secondary	 antibody	
(shown	in	Table	1)	for	35	minutes	followed	by	a	tertiary	layer	of	1:500	dilution	
of	 peroxidase-conjugated	 streptavidin	 (strep-HRP;	 DAKO).	 The	 slides	 were	
washed	with	PBS	3	times	for	5	minutes	each	in	between	all	three	layers.	Sections	
were	 then	 treated	with	3-diaminobenzidine-tetra-hydrochloride	solution	(DAB;	
Sigma,	 Poole,	 UK)	 for	 2-5	minutes	 followed	 by	washing	 in	 phosphate	 buffered	
saline	 (PBS)	 for	 5	 minutes.	 The	 slides	 were	 then	 counterstained	 with	 light	
haematoxylin,	dehydrated	through	increasing	concentrations	of	ethanol,	cleared	
in	xylene	and	mounted	 in	DPX	(mixture	of	distyrene,	a	plasticizer,	and	xylene).	
The	 negative	 control	 slide	 also	 underwent	 all	 the	 steps	 except	 that	 incubation	










Antibody	 Concentration	 Species	 Secondary	
Antibody	
Source	
p53	 1:300	 mouse	 Rabbit	anti	
mouse	biotin	
DAKO	
















TFF1	 1:400	 mouse	 Horse	anti	
mouse	biotin	
Abcam	







































































Intial	 studies	 into	 the	genetic	basis	of	Barrett’s	oesophagus	 (BO)	proposed	 that	
BO	is	a	clonal	lesion	from	which	a	carcinoma	can	arise.	However,	recent	work	has	
indicated	that	there	are	multiple	independent	clones	present;	therefore,	Barrett’s	




metaplasia,	 dysplasia	 and	 carcinoma	 by	 combining	 gland-by-gland	 mutation	
analysis	with	mapping	 onto	 tissue	 sections	 in	 an	 attempt	 to	 show	 evolution	 to	
cancer.	
	
To	 understand	 the	 evolutionary	 pathway	 leading	 to	 carcinoma	 development,	
several	studies	have	tried	to	reconstruct	phylogenetic	trees	within	human	breast	
(Navin	 and	 Hicks	 2010)	 and	 renal	 (Gerlinger,	 Rowan	 et	 al.	 2012)	 carcinomas.	
Genetic	heterogeneity	is	seen	in	various	stages	of	cancer	progression	(Marusyk	et	
al.,	2012).	Navin	et	al.,	1996,	have	shown	that	cancers	can	be	either	monogenomic	
(a	 single	 clone)	 or	 polygenomic	 (multiple	 independent	 clones).	 This	 raises	 an	
important	question	as	to	how	cancers	develop	in	polyclonal	diseases.	Thirlwell	et	










mutations	 in	 flow-purified	 whole	 biopsy	 specimens	 and	 proposed	 that	 BO	
develops	 as	 a	 clonal	 lesion	 and	 each	 additional	mutation	 undergoes	 a	 selective	
sweep	 through	 the	 lesion	 and	 becomes	 fixed	 i.e.,	 no	 wild	 type	 glands	 perisist	
(Maley	et	al.,	2004a).	 	 	However	Leedham	et	al.,	 (2008)	proposed	 that	Barrett’s	
progresses	 to	 cancer	 in	 a	 polyclonal	 fashion	 suggesting	 there	 are	 no	 founder	
mutations	 and	 not	 all	 mutations	 will	 become	 fixed	 and	 demonstrated	 this	 by	





Innes	 et	 al.,	 (2015)	 have	 shown	 by	 whole	 genome	 sequencing	 that	 dysplasia	
exhibits	multiple	dysplastic	clones	but	were	not	able	to	map	these	mutations	onto	
tissue	 sections	 (Ross-Innes	 et	 al.,	 2015).	 While	 the	 work	 in	 this	 chapter	 was	
performed	before	the	publication	of	whole	genome	sequencing	studies,	it	set	out	
to	 determine	 the	 relationship	 between	 polyclonal	 dysplasias	 and	 carcinomas,	
furthermore	 we	 do	 not	 know	 the	 geographical	 distribution	 of	 mutated	 glands	





The	 Barrett’s	 metaplasia-dysplasia-carcinoma	 sequence	 (MDC)	 is	 characterised	





1)	 To	 analyse	 individual	 gland	 clonal	 architecture	 of	 lesions	 representing	 the	
progression	of	Barrett’s	oesophagus	to	oesophageal	adenocarcinoma	and	to	infer	










DNA	was	macro-dissected	 (for	 details,	 refer	 chapter-2.	 Methods-2.2)	 from	 the	
dysplastic	 regions	 of	 EMR	 specimens	 and	 then	 screened	 for	 mutations	 in	 the	
variable	regions	of	p16INK4A,	TP53	and	KRAS	genes.	EMRs	&	Oesophagectomy	
specimens	with	an	identified	mutation	were	then	serially	sectioned,	and	glands	
were	 histologically	 graded	 and	 then	 microdissected	 using	 a	 P.A.L.M.	 laser	
capture	 microscope	 (chapters	 2.3	 and	 2.4).	 Glands	 were	 then	 sequenced	 (for	
sequencing	details,	see	chapter	2.6)	for	the	point	mutation	identified	in	the	initial	
screen.	 Maps	 indicating	 the	 mutation	 burden	 of	 each	 gland	 were	 constructed.	
Multiplex	 PCR	 was	 performed	 with	 a	 panel	 of	 microsatellite	 markers	 located	
within	 TP53	 (17q)	 SMAD4	 (18q)	 and	 CDKN2A	 gene.	 For	 each	 marker,	 loss	 of	
heterozygosity	was	 considered	 to	be	present	 if	 the	area	under	one	allelic	peak	
was	 less	 than	0.5	 times	or	more	 than	 two	 times	 the	area	of	 the	 corresponding	











Areas	 of	 dysplasia/cancer	were	 identified	 on	 a	 haematoxylin	 and	 eosin-stained	
section	by	two	pathologists,	and	these	areas	were	further	traced	onto	four	serial	

































1	 c.473G>A	 WT	 WT	 WT	 WT	 WT	
2	 WT	 WT	 c.722C>T	 WT	 WT	 WT	
3	 WT	 WT	 	 WT	 c.329G>A	 WT	
4	 WT	 WT	 WT	 c.814G>A	 WT	 WT	
5	 c.524G>A	 WT	 WT	 WT	 WT	 c.35G>A	
6	 c.487T>C	 WT	 WT	 WT	 WT	 WT	
7	 c.451C>T	 WT	 WT	 WT	 WT	 WT	
8	 WT	 WT	 c.743G>A	 WT	 WT	 WT	






















3.5.2	 Evolution	 of	 polyclonal	 Barrett’s	 to	 monoclonal	
oesophageal	adenocarcinoma:		
	
To	 determine	 the	 clonal	 evolution	 in	 my	 cohort	 of	 10	 EMRs	 and	
oesophagectomies,	 I	 laser-capture	 microdissected	 multiple	 glands	 from	 each	
specimen	and	individually	sequenced	them	for	the	mutations	identified	in	Table	
2	and	the	results	are	shown	in	Table	3.		I	performed	LOH	analysis	on	each	gland	
(also	 shown	 on	 Table	 3).	 I	 then	 mapped	 the	 genotype	 onto	 an	 H&E	 of	 each	




Four	 specimens	 (patient	 1,	 2,	 5,	 and	 10)	 displayed	 more	 than	 one	 clone	 in	
metaplasia	 and	 dysplasia	 (polyclonal),	 three	 specimens	 (patient	 4,	 6,	 and	 9)	
showed	monoclonal	 evolution	of	OA	 and	 two	 specimens	 (patient	 7	 and	8)	 only	
had	 dysplasia	 which	 was	 monoclonal.	 All	 identified	 adenocarcinomas	 were	
monoclonal	 regardless	 of	 the	 clonal	 status	 of	 the	 metaplasia	 and	 dysplasia.	
Patient	3	did	not	show	any	dysplasia	or	cancer	and	therefore	we	can	only	state	




















30/31	 (97%)	 –	 TP53	
WT	
1/31	 (3%)	 –	 TP53	
mutant	(c.473G>A)	
18/62	 (29%	 -	 TP53	
WT	









































































None	present	 4/4	 (100%)	 mutated	
for	TP53	(c.743G>A)	













































The	 results	 of	 the	 individual	 specimens	 clonal	 analysis	 are	 now	 described.	
Genotypic	analysis	of	metaplasia	from	patient	1	showed	the	presence	of	TP53	WT	
glands	(30/31	laser	captured	glands)	and	a	single	mutated	c.473G>A	metaplastic	
gland	(Figure	13).	Both	 these	clones	were	also	seen	 in	dysplasia	 from	the	same	
patient	(Figure	14).	Because	the	TP53	mutation	was	detected	 in	metaplasia,	 the	
presence	of	wild	type	and	mutated	dysplasia	must	suggest	a	polyclonal	dysplasia.	
It	 is	 interesting	 that	 the	 two	different	 clones	were	geographically	mixed	within	
the	dysplasia,	suggesting	that	the	rates	of	clonal	expansion	were	similar.	Spatially	























of	 metaplasia	 (A)	 and	 dysplasia	 (C).	 Mutational	 status	 of	 individual	 glands,	
indicating	 heterogeneity	 in	 Barrett’s	 metaplasia	 and	 dysplasia	 (B	 and	 D	





Figure	 14:	 Spatial	 distribution	 of	 metaplastic	 and	 dysplastic	 gland	
genotypes	in	the	second	EMR	specimen	from	patient	1.			
(A)	 H&E	 of	 the	 EMR	 from	 patient	 1	with	 high	 powered	 images	 of	metaplastic	
glands	(B)	and	dysplastic	glands	(C).	The	mutational	status	of	individual	glands	
(TP53	 mutated	 =	 yellow,	 WT=green)	 (D).	 Sanger	 sequencing	 tracing	
demonstrating	the	TP53	c.473G>A	muations	(E).	Overall	most	dysplastic	glands	









In	 a	 separate	 section	 from	 patient1,	 there	 is	 identifiable	 dysplasia	 and	
adenocarcinoma	present.	 The	 genotype	 of	 each	microdissected	 gland	has	 been	














wild	 type	 dysplastic	 gland	 (yellow)	 or	mutated	 (pink)	 for	TP53	 (722C>T)	 (B).	






Figure	 17:	 2-dimensional	 map	 illustrating	 spatial	 distribution	 of	 mutant	
glands	in	dysplasia	and	metaplasia	from	patient	2.		
H&E	 of	 an	 EMR	 with	 Barrett’s	 high-grade	 dysplasia	 (A).	 Magnified	 images	 of	
Barrett’s	 metaplasia,	 dysplasia	 and	 carcinoma	 (B,	 C	 and	 D	 respectively).	 The	
majority	 of	 glands	 were	 mutated	 for	 TP53	 (722C>T),	 some	 metaplastic	 and	
dysplastic	 glands	 were	 wild	 type	 for	 TP53	 (E	 and	 F	 respectively)	 suggesting	
polyclonality.	 The	 carcinoma	 was	 monoclonal	 for	 TP53	 (722C>T)	 (G).	 Most	












both	 clones	 identified	 in	 the	metaplasia	 progressed	 to	 dysplasia	 and	 the	TP53	
LOH	clone	acquired	additional	TP53	and	KRAS	mutations	with	time.	All	8	areas	of	
the	cancer	section	were	also	mutated	for	TP53	&	KRAS	mutation	with	TP53	LOH	




metaplasia	 Clone-1:	 CDKN2A	 mutant	 c.382C>T)	 and	 three	 clones	 in	 dysplasia	
(Clone-1:	 c.442G>A	 Clone-2:	 c.442G>A	 and	 c.382C>T,	 Clone-3:	 c.409A>G).	 My	
work	involved	screening	the	cancer	specimen	from	the	same	patient.	Eight	out	of	
8	cancer	areas	were	monoclonal	for	CDKN2A	mutant,	c.442G>A.	(Figure	19).	
These	 observations	 show	 genetic	 diversity	 within	 Barrett’s	 metaplasia	 and	









H&E	 of	 from	 the	 EMR	 from	 patient	 5	 showing	 different	 gland	 phenotypes	 (1).	

















3.5.3	 Evolution	 of	 monoclonal	 Barrett’s	 to	 oesophageal	
adenocarcinoma:		
	
Three	 specimens	 (patient	 4,	 6,	 and	9)	 showed	monoclonal	 evolution	of	OA	 and	
two	 specimens	 (patient	 7	 and	 8)	 only	 had	 dysplasia	which	was	monoclonal.	 In	
patient	 4,	 the	 EMR	 displayed	 metaplasia,	 dysplasia	 and	 carcinoma.	 Individual	
glands	were	 laser-captured	 and	 the	 sequenced	 for	TP53	 mutation.	 Four	 out	 of	
eight	metaplastic	 glands	were	WT	 and	 remaining	 four	metaplastic	 glands	were	
mutated	 for	 TP53	 (c.487T>C)	 (Figure	 20),	 suggesting	 at	 least	 two	 clones	 in	
metaplasia.		Ten	out	of	ten	dysplastic	glands	were	mutated	for	TP53	(c.487T>C),	
suggesting	 that	 only	mutated	 clone	 progressed	 to	 dysplasia	 (Figure	 21).	 Thirty	
small	 areas	 of	 cancer	 were	 laser-captured	 to	 check	 heterogeneity	 in	 cancer.	
However,	 all	 30	 laser-captured	 areas	 were	 mutated	 for	 TP53	 (c.487T>C,	 see	
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(A)	 Haematoxylin	 and	 Eosin	 staining	 of	 metaplasia	 tissue	 from	 patient	 4.	 (B)	
Magnified	H&E	image	from	patient	4	specimen,	showing	metaplastic	glands.	(C)	
Multiple	metaplastic	 glands	 laser	 captured,	 some	were	WT	 for	TP53	mutation	












(A)	 Haematoxylin	 and	 Eosin	 staining	 of	 dysplasia	 tissue	 from	 patient	 4.	 (B)	
Magnified	 H&E	 image	 from	 patient	 4	 specimen,	 showing	 dysplastic	 glands	 (C)	












The	EMR	 specimen	 from	patient	 9	 showed	 areas	 of	 dysplasia	 and	 cancer.	 Five	
individual	 glands	 were	 laser	 captured	 from	 the	 dysplastic	 area	 and	 all	 5	









dysplastic	 and	 cancer	 glands	 shown	 in	 Figure	 23.	 These	 demonstrate	 the	









Multiple	 clones	were	 identified	 in	Barrett’s	metaplasia	 and	dysplasia,	whereas,	
only	 one	 clone	 progressed	 to	 carcinoma,	 suggesting	 monoclonal	 Barrett’s	
adenocarcinoma	 from	polyclonal	Barrett’s	metaplasia	and	dysplasia	 in	 some	of	
the	cohort	studied	here.	
	
3.5.5	 Heterogeneity	 at	 the	 protein	 level:	 Correlation	 between	
TP53	mutational	status	and	p53	protein	expression:		
Numerous	 studies	 have	 evaluated	 the	 expression	 pattern	 of	 p53	 and	 its	
correlation	with	 the	grade	of	dysplasia	and	 the	 risk	of	progression	 to	OA.	TP53	
mutations	 are	 found	 in	 all	 stages	 of	 MDC	 associated	 with	 p53	 expression	
(Hamelin	 et	 al.,	 1994).	 Interestingly,	 the	 results	 of	 numerous	
immunohistochemical	 studies	 have	 demonstrated	 a	 strong	 p53	 protein	
overexpression	in	more	than	50%	of	OA	(Hamelin	et	al.,	1994,	Younes	et	al.,	1993,	
Neshat	 et	 al.,	 1994).	 Younes	 et	 al.,	 (1993),	 have	demonstrated	 that	p53	protein	
accumulation	 increases	 with	 severity	 of	 histology,	 such	 as	 from	 low-grade	 to	
high-grade	dysplasia	(Younes	et	al.,	1993).	Increased	expression	of	p53	has	been	
correlated	with	 increased	 proliferation	 in	 the	 progression	 of	 Barrett’s	 to	OA	 in	
some	studies	 (Hritz	et	al.,	2009,	Binato	et	al.,	2009).	A	positive	predictive	value	
for	 neoplastic	 progression	 is	 seen	 in	patients	with	 LGD	 (15%	progression)	 and	
LGD	 with	 positive	 p53	 expression	 (33%	 progression)	 (Kastelein	 et	 al.,	 2013).	
Potentially	 this	 could	 be	 used	 as	 a	 valuable	 biomarker	 in	 the	 prediction	 of	 an	
increased	risk	of	disease	progression	in	patients	with	Barrett’s.		
	
Identifying	TP53	mutated	 glands	 is	 a	 time	 consuming	 process.	 To	 simplify	 this	
procedure,	 I	 attempted	 to	 correlate	 TP53	 mutations	 with	 p53	





become	 stabilised	 and	 accumulates	 within	 the	 cell.	 This	 can	 be	 detected	 by	
immunohistochemistry.	 Here	 I	 investigate	 if	mutation	 status	 is	 correlated	with	
protein	 expression	of	microdissected	Barrett’s	 glands.	TP53	mutated	EMRs	and	
oesophagectomy	 specimens	 (n=4)	 showing	 all	 stages	 of	 MDC	 were	
immunostained	 for	 p53	 expression.	 Three	 out	 of	 four	 specimens	 expressed	
variable	levels	of	p53	and	the	remaining	specimen	did	not	express	p53.	P53	was	
not	 expressed	 in	 areas	 of	 metaplasia	 (Figure	 24);	 dysplastic	 glands	 fully	
expressed	 p53	 or,	 at	 least,	 showed	 partial	 expression	 (Table	 4).	 The	 areas	 of	
cancer	fully	expressed	p53.		In	Metaplasia;	a	few	glands	were	mutated	for	TP53	–	
Exon	7	(Figure	24D),	but	none	expressed	p53	(Figure	24E).	In	dysplasia;	mutated	



























Table	 4:	 Comparing	 the	 mutational	 status	 of	 different	 Barrett’s	 gland	
phenotypes	and	genotypes	with	p53	expression.			































These	 studies	 failed	 to	demonstrate	any	significant	 relationship	between	
protein	 expression	 and	mutation	 status	 (Figure	24	 and	25	 and	Table	4).	
p53	 expression	 is	 variable:	 not	 all	 TP53	 mutations	 stabilise	 the	 protein	
	
95	




























a	 genetically	 clonal	 lesion	 from	which	 cancer	 can	 arise	 (Galipeau,	 Prevo	 et	 al.	





outgrowths	 from	 polyclonal	 Barrett’s	 dysplasia.	 Phenotypic	 and	 genotypic	
heterogeneity	 is	 detected	 between	 glands	 mixed	 through	 each	
EMR/oesophagectomy	 specimen.	 Gland-by-gland	 sequencing	 analysis	 has	
identified	 the	 presence	 of	 multiple	 clones	 within	 Barrett’s	 dysplasia	 that	 may	
have	 been	missed	 even	 by	 next	 generation	 sequencing	 due	 insufficient	 depth.		
Nevertheless,	data	that	has	been	obtained	from	whole	genome	and	whole	exome	
sequencing	 studies	 have	 confirmed	 that	 Barrett’s	 dysplasia	 is	 a	 heterogenous	
lesion	 and	 displays	 polyclones	 (Weaver	 et	 al.,	 2014,	 Timmer	 et	 al.,	 2015).	 My	
data	 has	 also	 shown	 that	 invasive	 oesophageal	 adenocarcinomas	 appear	 as	
clonal	 outgrowths	 from	 the	 surrounding	 polyclonal	 Barrett’s	 dysplasia	
suggesting	that	‘winner’	clones	can	now	be	identified	using	histological	sections.	
This	 suggests	 that	 there	 may	 be	 a	 cellular	 interaction	 between	 different	











the	 change	 of	 pathology	 from	metapasia	 to	 dysplasia	 and	 dysplasia	 to	 cancer.		
The	change	in	pathology	is	likely	to	be	due	to	either	other	genomic	defects,	such	
as	 mutations	 in	 SMAD4,	 ARID1A	 and	 SMARCA4,	 copy	 number	 changes	 or	 a	
combinations	of	genetic	events	that	occur	simultaneously	(Weaver	et	al.,	2014).		
	
Recently,	 a	 case-cohort	 follow-up	 study	 by	 Li	 et	 al.,	 have	 used	 SNP	 arrays	 to	
investigate	 genetic	 alterations	 in	 Barrett's	 patients	 who	 progressed	 to	 OA	
(progressors)	and	patients	who	did	not	progress	 to	OA	(non-progressors)	over	




of	 cancer	 (Li	 et	 al.,	 2014).	 Similar	 results	were	 shown	 by	 Timmer	 et	 al,	 2015,	
suggesting	 that	 genetic	 diversity,	 defined	 by	 an	 abnormal	 marker	 count	 of	
alterations	 in	CDKN2A,	MYC	 and	 aneusomy	 could	 be	 used	 to	 identify	 high-risk	
patients	with	non-dysplastic	Barrett's	(Timmer	et	al.,	2015).	TP53	and	CDKN2A	
commonly	mutated	 in	OA,	http://www.sanger.ac.uk/cosmic	 and	a	 limitation	of	
this	study	is	that	the	whole	genome	was	not	sequenced.	Ross-Innes	et	al.,	(2015)	
have	 shown	 by	 whole	 genome	 sequencing	 that	 dysplasia	 exhibits	 multiple	
dysplastic	 clones	 BO	 demonstrates	 various	 mutations	 suggesting	 polyclonality	
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even	 in	 the	 absence	 of	 dysplasia	 within	 the	 specimens.	 They	 have	 also	
demonstrated	 that	 OA	 shows	 genetic	 heterogeneity	 with	 very	 few	 common	
mutations	 between	 OA	 and	 the	 adjacent	 BO,	 but	 were	 not	 able	 to	 map	 these	




the	 genomic	 resolution	 is	 low.	 These	 observations	 support	 my	 findings	 that	
mutations	 in	TP53	 and	CDKN2A	may	not	 be	 the	 only	dysplasia	 causing	 genetic	
alterations.	
	
Detecting	 mutations	 or	 genetic	 heterogeneity	 in	 a	 tissue	 sample	 involves	
considerable	use	of	 time	and	resources:	hence,	 it	 is	 important	 to	use	easier	and	
reliable	 methods	 such	 as	 p53	 immunostaining	 in	 an	 attempt	 to	 reflect	 the	
underlying	mutational	status	of	a	sample.	Around	72%	of	OA	express	p53	(Binato	
et	 al.,	 2009).	 However,	 not	 all	TP53	 mutations	 stabilise	 the	 protein,	 leading	 to	
accumulation	in	the	cell	(Hamelin	et	al.,	1994).	The	recent	case-control	study,	to	
evaluate	 the	p53	protein	 expression	 in	 the	progression	of	BO	 to	OA	has	 shown	
that	p53	expression	is	associated	with	an	increased	risk	of	neoplastic	progression	
in	Barrett's	MDC.	The	positive	predictive	value	of	aberrant	p53	expression	when	
compared	 to	 the	 histological	 diagnosis	 of	 LGD	 15%	 and	 33%	 respectively,	
suggesting	 that	 aberrant	 p53	 expression	 is	 a	 better	 predictor	 of	 neoplastic	
progression	(Kastelein	et	al.,	2013).	In	my	study,	both	non-mutated	and	mutated	






that	mdm-2	 is	 differentially	 expressed	 in	 wild-type	TP53	 cancers	 compared	 to	
TP53	 mutated	 cancers	 (Soslow	 et	 al.,	 1999).	 This	 Indicates	 that	 mdm-2	
expression	may	 be	 responsible	 for	 p53	 stabilization	 and	 loss	 of	TP53	 function.	
Data	 presented	 here	 shows	 that	 immunostaining	 for	 p53	 does	 not	 reflect	 the	
underlying	 mutational	 status	 of	 the	 individual	 gland.	 Future	 work	 on	
immunostaining	 for	 regulators	 of	 p53	 expression	 such	 as	mdm-2	 expression	 in	
BO	and	OA	may	better	identify	mutant	versus	wild	type	clones.	
	
Darwinian	 selection	 states	 that	 the	 fittest	 organism	 survives	 to	 dominate	
(positive	selection)	and	the	weaker	organisms	get	eliminated	(negative	selection).	
In	BO,	mutant	clones	may	interact	with	each	other	competing	for	fixation	(clonal	
interference),	 and	 thus,	 a	 winning	 clone	 would	 acquire	 sufficient	 growth	
advantage	 to	 become	 carcinoma.	 According	 to	 the	 somatic	 mutation	 theory	 of	
carcinogenesis,	 a	 single	 founder	mutation	 arising	 from	 the	 progeny	 of	 a	 single	
stem	 cell	 acquires	 a	 selective	 growth	 advantage	 over	 its	 predecessors	 and	
neighbouring	 cells	 as	 it	 acquires	 more	 driver	 mutations	 (Maley	 et	 al.,	 2004a).	
However,	 Leedham	 et	 al.,	 have	 shown	 that	 multiple	 independent	 clones	 exist	
within	 Barrett’s	 (Leedham	 et	 al.,	 2008).	 Here,	 I	 have	 shown	 that	 polyclonal	
premalignant	tissue	is	common	in	patients	with	dysplasia	but	only	a	single	clone	






There	 are	 three	 possible	 factors	 which	 may	 dictate	 why	 Barrett’s	 OA	
demonstrates	 a	 monoclonal	 origin	 and	 not	 a	 polyclonal	 origin	 as	 shown	 in	
dysplasia.	 	 First,	 given	 enough	 time	 in	 a	 slow	 growing	 cancer,	 each	 dysplastic	
clone	may	have	the	potential	to	become	malignant	but	the	rate	of	progression	to	
cancer	is	such	that	the	first	clone	to	do	so	ends	up	killing	the	patient	before	other	
dysplastic	 clones	 can	 evolve.	 	 Second,	 the	 selective	 advantage	 of	 the	 winner	
dysplastic	clone	is	such	that	it	outcompetes	the	loser	clone	essentially	preventing	
it	 becoming	 malignant.	 This	 raises	 the	 possibility	 that	 clones	 interact	 and	
compete	or	cooperate	to	form	a	cancer.		This	has	been	demonstrated	by	Miller	et	
al.,	 who	 isolated	 several	 tumour	 cells	 from	 a	 single	 breast	 tumour	 from	
BALB/cfC3H	 chimeric	 mice	 and	 established	 sublines	 in	 vitro.	 When	 neoplastic	
cells	 from	 the	 same	 or	 different	 sublines	 were	 injected	 into	 opposite	 flanks	 of	
mice,	each	inhibited	the	others	growth	(Miller	et	al.,	1980).	Conversely,	Wu	et	al.,	
have	 shown	 that	mutant	 clones	 can	 cooperate	 to	 form	 a	 cancer.	 Using	mutant	
Drosophila	as	a	model,	Scrib-/-	cells	promote	the	neoplastic	development	of	Rasv12	
cells	and	produce	larger	tumours	when	compared	to	flies	that	only	possess	one	of	




1984).	 By	 understanding	 the	 genetic	 characteristics	 of	 dominant	 clones	 and	
where	they	fit	into	the	fitness	landscape	in	premalignant	disease,	the	evolution	of	
the	 neoplasm	 may	 be	 predicted.	 Identification	 of	 differential	 expression	 of	




malignancy	 and	 help	 to	 identify	 a	 high-risk	 group	 patient	 for	 developing	
carcinoma.	Fundamental	to	this	is	the	mechanism	of	clonal	expansion	of	mutant	
clones	in	BO.		Clones	expand	via	crypt	fission	in	the	colon	(Greaves	et	al.,	2006),	in	
the	 small	 intestine	 (Gutierrez-Gonzalez	 et	 al.,	 2009)	 and	 in	 the	 gastric	mucosa	
(McDonald	et	al.,	2008).	In	gastric	intestinal	metaplasia	(Gutierrez-Gonzalez	et	al.,	
2009)	patches	of	clonally	identical	glands	are	seen,		suggesting	that	gland	fission	
is	 the	 process	 underlying	 this	 expansion.	 	 Recently,	 patches	 of	 Barrett’s	 glands	
have	been	shown	 to	be	 clonal	populations,	 and	Barrett’s	mucosa	 contains	 large	
groups	of	 clonally	 identical	 glands	 (Nicholson	 et	 al.,	 2011).	 It	 appears	probable	
that	 mutant	 clones	 involved	 in	 the	 development	 of	 Barrett's	 dysplasia	 also	
clonally	expand	via	gland	fission,	probably	with	a	growth	advantage	conferred	by	
the	p16	or	TP53	mutation.	On	the	other	hand,	 immediately	adjacent	glands	may	
not	 be	 derived	 from	 the	 same	 clone	 (Rhiner	 and	 Moreno,	 2009).	 There	 is	 no	
evidence	 that	 Barrett’s	 segments	 increase	 in	 length	 with	 time	 (Gatenby	 et	 al.,	
2007).			
	
Martens	 and	 colleagues	 (Martens	 et	 al.,	 2011,	 Martens	 and	 Hallatschek,	 2011)	
have	drawn	attention	to	the	fact	that	many	pre-cancerous	tissues	have	a	distinct	
spatial	structure,	which	will	impinge	in	the	manner	in	which	clones	expand.	Such	




invasion	 occurs	 in	 pre-invasive	 lesions	 such	 as	 Barrett’s	 (Spechler,	 2003),	
inflammatory	 bowel	 disease	 (Jess	 et	 al.,	 2006)	 and	 most	 colorectal	 adenomas	
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(Hofstad	 et	 al.,	 1996).	 The	 present	 work	 shows	 the	 existence	 of	 multiple	
contiguous	but	genotypically	different	clones.	According	to	Martens	et	al.,	clones	
which	are	 smaller	 in	 size,	 grow	 in	a	 linear	pattern	with	 time	until	 they	 reach	a	





Studying	 clonal	 evolution	 and	 genetic	 diversity	 may	 lead	 towards	 the	
development	of	genetic	biomarkers	 for	 the	prediction	of	neoplastic	progression	
in	patients	with	BO	 (Andor	et	 al.,	 2016).	To	 interpret	 the	genetic	diversity	 as	 a	





not	 accurately	predict	 the	 likelihood	of	 cancer	progression	 (Merlo	 et	 al.,	 2006).	
Maley	et	al.,	in	their	prospective	study	of	cancer	as	an	outcome,	have	shown	that	a	































Dysplasia	 is	 the	 only	 clinical	 risk	 factor,	 which	 predicts	 progression	 to	 OA.	 It	
represents	 pre-invasive	 disease	which	 requiring	 intervention.	 Dysplasia	 can	 be	
morphologically	 described:	 nuclear	 hyperchromatism	 with	 or	 without	
pleomorphism	 increased	 mitosis,	 loss	 of	 polarity	 and	 differentiation	 (Bignold,	
2003).	It	has	also	been	suggested	that	definition	of	dysplasia	should	also	include	
morphological	 changes	 involving	 the	 entire	 length	 of	 gland/crypt	 and	 also	 the	
surface	 epithelium	 (Reid	 et	 al.,	 1988,	 Riddell	 et	 al.,	 1983).	 Glands/crypts	 with	
‘surface	maturation’	are	often	termed	as	‘reactive’	and	are	dismissed	for	dysplasia.	




However,	 genetic	 changes,	which	 are	 responsible	 for	 this	 change	 in	 phenotype,	
are	 unknown.	 There	 is	 enough	 evidence	 to	 suggest	 that	 Barrett’s	 dysplasia	 is	
irreversible:	 in	 basal	 crypt	 dysplasia-like	 atypia	 (BCDA),	 obvious	 dysplastic	
changes	 occur	 in	 Barrett’s	 glands	 and	 other	 gastrointestinal	 pre-malignant	
lesions;	however,	the	upper	gland/crypts	associated	with	these	dysplastic	glands	





In	BCDA;	 cellular	 atypia	 is	 restricted	 to	 the	 base	 of	 gland	or	 crypt,	without	 the	
involvement	 of	 upper	 half	 of	 the	 gland	 or	 crypt	 and	 the	 surface	 epithelium.	
Recently,	Odze	and	Maley	et	al.,	have	shown	the	significance	of	BCDA	in	BO	but	
also	 in	 stomach,	 inflammatory	 bowel	 disease	 and	 colonic	 adenomas	 (Odze	 and	
Maley,	2010).	Lomo	et	al.,	have	shown	that	BCDA	in	BO	is	associated	with	LGD	or	
HGD	 or	 even	 OA	 elsewhere	 in	 the	 oesophagus.	 They	 have	 also	 shown	 that	 BO	
associated	with	BCDA	showed	increased	incidence	of	TP53	LOH,	aneuploidy	and	
proliferation	 (indicated	 by	 Ki67	 staining	 and	 p53	 immunohistochemistry)	
compared	to	control	group	(Lomo	et	al.,	2006).		
	
Recently,	 combined	 efforts	 from	 6	 gastrointestinal	 pathologists	 to	 evaluate	 the	
criteria	 and	 reproducibility	 in	 the	 diagnosis	 of	 BCDA	 showed	 that	 there	 was	
moderate	 interobserver	 agreement.	 BCDA	 may	 be	 of	 low-grade	 or	 high-grade	
depending	on	 the	degree	of	 cellular	atypia	and	crypt	branching.	The	basal	 cells	
are	mucin	depleted,	however,	the	surface	epithelium	consist	of	mucous	secreting	
cells	 with	 regenerative	 changes	 (Coco	 et	 al.,	 2011).	 Two	 years	 follow-up	 of	
patients	 with	 BCDA	 showed	 that	 87%	 of	 BO	 patients	 with	 BCDA	 had	 either	
synchronous	 or	 metachronous	 dysplasia	 or	 OA	 elsewhere	 in	 the	 oesophagus	
(Lomo	et	al.,	2006).	It	was	also	suggested	that	dysplasia	in	BO	begins	at	the	bases	
of	 the	glands,	which	 further,	 in	 time	progresses	 to	 involve	 the	entire	gland	and	
surface	 epithelium	 (Coco	 et	 al.,	 2011).	 However,	 what	 is	 not	 clear	 is;	 whether	
dysplastic	cells	at	 the	base	of	 the	gland	share	 the	same	genetic	alterations	with	
cells	 present	 in	 the	 upper	 portion	 of	 the	 gland.	 The	 technical	 problem	 lies	 in	
	
106	


















Patients:	 A	 total	 of	 17	 patient	 specimens	 (Formalin-fixed,	 paraffin-embedded-
FFPE)	 were	 obtained	 from	 patients	 undergoing	 biopsy	 for	 monitoring	 of	 BO.	





(Table	 5),	 of	 which	 three	 specimens	 were	 inconclusive	 either	 due	 to	 lack	 of	




were	 then	 serially	 sectioned,	 and	 two	 independent	 pathologists	 histologically	
graded	 glands.	 The	 dysplastic	 gland	 bases	 and	 the	 associated	maturing	 upper	
glands	 and	 surface	 epithelium	were	 differentially	microdissected	 using	 a	 laser	
capture	microscope	(for	LCM	and	PCR	details,	refer	chapter-2,	Methods-2.3	and	










with	 the	 differentiating	 surface	 epithelium	 so	 that	 it	 could	 be	 reasonably	
proposed	that	 the	glands	displaying	BCDA	were	supplying	cells	 to	 the	maturing	
surface	epithelium.	Below	is	a	magnified	H	&E	of	Barrett’s	gland;	the	basal	cells	




















In	 a	 cohort	 of	 45	 Barrett’s	 specimen’s,	 17	 had	 identifiable	 glands	 with	 BCDA.	
Glandular	tissue	was	macrodissected	from	these	cases	and	screened	for	somatic	
gene	 mutations	 in	 TP53,	 CDKN2A	 and	 KRAS.	 The	 screening	 results	 of	 these	
samples	 have	 been	 shown	 in	 Table	 5	 below.	 5	 out	 of	 17	 specimens	 had	
identifiable	 mutations.	 It	 was	 frequently	 found	 that	 the	 complexity	 of	 the	
architecture	in	Barrett’s	mucosa	meant	that	only	2	patients	showed	glands	where	
their	 bases	were	 in	 direct	 continuity	 with	 the	 surface	 epithelium	 could	 not	 be	













The	 2	 patients	 put	 forward	 for	 clonal	 analysis	 showed	 low-grade	 BCDA	 with	
maturing	gland	epithelium	in	continuity	with	the	dysplastic	glands.	Patient	1	was	
a	 female	 aged	 72	with	 a	 history	 of	 long	 segment	Barrett’s	 oesophagus	 of	more	
than	ten	years.	Patient	2	was	a	66	male	also	with	a	long	history	of	long	segment	
Barrett’s	 oesophagus.	 	 Neither	 patient	 had	 a	 history	 of	 dysplasia.	 In	 this	 study,	
both	 patients	 had	 CDKN2A	 mutation,	 which	 was	 clonal	 for	 the	 entire	 gland	




patient	2,	non-dysplastic	 epithelium	without	 any	evidence	of	BCDA	showed	 the	
same	CDKN2A	mutation	(Figure	29),	and	it	is	most	likely	that	the	CDKN2A	mutant	












red.	 B)	 Both	 the	 basal	 gland	 dysplasia	 and	 the	 maturing	 surface	 epithelium	
shares	 the	 same	 C238T	mutation	 in	 CDKN2A.	 C)	 LCM	 areas.	 Thus	 the	 surface	





























This	 study	 shows	 that	 Barrett’s	 glands	 consisting	 of	 basal	 crypt	 dysplasia-like	
atypia,	 characterised	 by	 basal	 cells	 displaying	 features	 of	 dysplasia-like	 atypia	





This	 study	 has	 also	 shown	 that	 even	 after	 acquiring	 genetic	 alteration,	 such	 as	
mutation	 in	 CDKN2A	 tumour	 suppressor	 gene,	 the	 Barrett's	 gland	 retained	 its	
healthy	glandular	organization	and	certainly	did	not	show	evidence	of	dysplasia.	





This	 study	 has	 shown	 that	 dysplastic	 Barrett’s	 glands	 can	 consist	 of	 two	
phenotypically	 distinct	 cells,	 in	 which	 basal	 cells	 with	 dysplasia	 and	 surface	
maturation	 cells	 share	 a	 common	 somatic	 CDKN2A	 gene	 mutation,	 suggesting	
that	 these	 cells	 share	 a	 common	 ancestry	 and	 are	 clonal	 in	 origin.	 These	
observations	 confirm	 that	 basal	 dysplastic	 cells	 give	 rise	 to	 the	 surface	





In	BO,	 the	dysplastic	 cell	biology	and	 its	progression	within	a	gland	 is	not	very	
well	 understood	 (Odze	 and	 Maley,	 2010).	 Recently	 it	 has	 been	 shown	 that	
multipotential	 stem	 cells	 in	 BO	 reside	 in	 the	middle	 portion	 of	 Barrett’s	 gland	
giving	rise	to	their	clonal	progeny	(Lavery	et	al.,	2014b).	In	Familial	Adenomatous	
Polyposis	(FAP),	a	second	hit	on	the	second	allele	of	APC	gene	causes	a	change	in	
the	 phenotype	 of	 the	 entire	 colonic	 crypt	 to	 dysplasia	 (Lamlum	 et	 al.,	 2000).	
However,	 in	 the	stomach;	 intestinal	metaplasia	 found	adjacent	 to	dysplasia	was	
mutated	 for	 APC	 gene,	 but	 did	 not	 show	 any	 evidence	 of	 dysplasia	 (Gutierrez-
Gonzalez,	 Graham	 et	 al.	 2011).	 Suggesting,	 that	 gene	 mutations	 may	 not	
necessarily	 lead	to	a	change	 in	gland	phenotype,	 the	genetic	 interactions	within	
the	niche	may	play	a	vital	role.		
	
It	 has	 been	 shown	 that	 BO	 with	 glands	 containing	 BCDA	 are	 associated	 with	
either	 synchronous	 or	 metachronous	 dysplasias	 or	 OAs	 elsewhere	 in	 the	
oesophagus	 (Lomo	 et	 al.,	 2006,	 Coco	 et	 al.,	 2011).	 It	 has	 also	 been	 shown	 that	
these	pre-tumour	clones	can	form	large	patches,	expanding	areas	of	up	to	17cm	
of	a	Barrett’s	segment	(Barrett	et	al.,	1999,	Wong	et	al.,	2001,	Maley	et	al.,	2004a).	
This	 has	 also	been	observed	 in	non-dysplastic	 tissue	 in	 ulcerative	 colitis	which	
can	 also	 carry	 a	 substantial	 mutational	 burden	 without	 phenotypic	 changes	
(Leedham	et	al.,	2009).	This	raises	the	question	of	the	acceptability	of	dysplasia	











This	 study	 has	 shown	 that	 entire	 gland	 with	 BCDA	 share	 a	 clonal	 mutation:	
suggesting	 that	 dysplasia	 can	 respond	 to	 environmental	 differentiation	 signals,	
indicating	 us	 to	 re-visit	 the	 biology	 of	 dysplasia	 and	 also	 to	 understand	 the	






























undergone	 oesophagectomy	 for	 OA	 (O'Riordan	 et	 al.,	 2004b,	 Hamilton	 and	
Yardley,	1977).	This	project	investigates	the	clonal	relationship	between	neo-BO	
and	 their	 original	 carcinoma.	 Approximately	 50%	 of	 patients	 develop	 neo-
Barrett’s	following	surgery	for	OA	of	which	27%	of	patients	displayed	specialised	
intestinal	 metaplasia	 (O'Riordan	 et	 al.,	 2004b).	 Therefore,	 there	 is	 a	 need	 to	
investigate	 the	 origins	 of	 neo-Barrett’s	 to	 assess	 the	 efficacy	 of	 the	 cancer	
surgery	 and	 the	 tumourigenic	 potential	 of	 neo-Barrett’s.	 Most	 patients	
presenting	with	BO	developed	metaplasia	many	years	before	diagnosis.	Neo-BO	
provides	us	with	an	opportunity	 to	 investigate	 the	origin	of	a	newly-developed	
Barrett’s	 lesion.	 Here	 I	 analyse	 the	 mutational	 status	 of	 the	 original	 resected	
oesophageal	carcinoma	specimens	and	compare	these	to	the	mutational	status	of	
the	neo-Barrett’s	 lesions.	 Identifying	 the	same	clone	 in	 the	original	OA	and	 the	
















clear	as	 to	which	phenotype	progresses	or	 increases	 the	 risk	of	developing	OA	
(Chandrasoma	et	al.,	2012,	DeMeester	and	DeMeester,	2000).	Recently,	Lavery	et	
al.,	have	shown	that	the	proliferative	zone	and	stem	cell	niche	in	Barrett’s	gland	










oesophagectomy,	 remaining	 stomach	 is	 joined	 to	 the	 remaining	 cervical	
oesophagus,	which	has	 hardly	 been	 exposed	 to	 acid	 reflux.	 Endoscopic	 studies	













the	 histological	 features	 of	 neo-BO.	 Histological	 examination	 of	 neo-BO	 has	
shown	that	columnar	metaplasia	showed	60%	gastric-cardiac	type,	20%	gastric-
fundic	 type	 and	 20%	had	 IM	 consisting	 of	 goblet	 cells.	 The	 time	 taken	 for	 the	
appearance	 of	 IM	 since	 oesophagectomy	 was	 longer	 compared	 with	 those	





















Cytokeratin	 (CK)	 is	 a	 keratin	 protein,	 present	 in	 the	 cytoplasm	 of	 glandular	
epithelium.	CK7,	which	is	a	marker	of	ductal	differentiation,	 is	not	expressed	in	
the	 normal	 oesophagus.	 Ormsby	 et	 al.,	 have	 shown	 that	 CK7	 was	 expressed	




in	 the	 superficial	 epithelium	of	BO.	This	pattern	was	not	 seen	 in	biopsies	 from	
gastric-cardia	and	gastric	resection	specimen	with	features	of	IM	(Ormsby	et	al.,	
1999).	100%	of	Barrett’s	oesophagus	tissue	sections	stain	positive	for	CK7/CK20	
of	 which	 78%	 contain	 IM	 at	 the	 GOJ	 and	 none	 for	 the	 stomach.	 DAS-1	 is	
expressed	 in	 incomplete	 type	 colonic	 intestinal	 metaplasia,	 Lord	 et	 al.,	 have	
shown	that	DAS-1	was	significantly	expressed	in	BO	and	IM	at	GEJ	compared	to	




























(chapters	 2.3	 and	 2.4).	 Glands	 were	 sequenced	 (chapter	 2.6)	 for	 the	 point	
mutation	identified	in	the	initial	screen	of	their	OA.	Cellular	proliferation	within	
neo-BO	gland	was	assessed	using	Ki67.	Immunohistochemistry	was	used	to	stain	






To	 determine	 whether	 neo-BO	 is	 a	 de	 novo	 lesion	 or	 is	 a	 result	 of	 field	
cancerization,	 25	 oesophagectomy	 specimens	were	 screened	 (Table	 6);	macro-
dissected	tissue	was	screened	for	mutations	in	genes	known	to	be	mutated	in	OA	










Biopsy	 specimens	 form	 neo-BO	 of	 all	 eleven	 patients	 who	 had	 identifiable	
mutations	in	their	OA	were	screened	for	other	commonly	mutated	genes	(TP53,	
CDKN2A	and	KRAS).	Mutations	identified	in	OA	were	not	present	in	any	of	neo-BO	
specimens	 (Table	 6).	 14	 other	 patients	 did	 not	 display	 any	 mutations	 in	 the	
limited	number	of	genes	sequenced.	
	
Patient	 Oesophagectomy	 Cancer	mutation	 Present	in	Neo	
Barrett’s?	
1	 Adenocarcinoma	 c.35G>A	KRAS	 No	
2	 Adenocarcinoma	 c.743G>A	TP53	 No	
3	 Adenocarcinoma	 c.238C>A	CDNK2A	 No	
4	 Adenocarcinoma	 c.820G>A	TP53	 No	
5	 Adenocarcinoma	 c.451C>T	TP53	 No	
6	 Adenocarcinoma	 c.844C>T	TP53	 No	
7	 Adenocarcinoma	 c.677C>T	TP53	 No	
8	 Adenocarcinoma	 c.853G>T	TP53	 No	
9	 Adenocarcinoma	 c.527G>C	TP53	 No	
10	 Adenocarcinoma	 c.742C>T	TP53	 No	










5.5.2	 Laser	 capture	 microscopic	 dissestion	 and	 sequencing	
individual	neo-BO	gland:	


























bases	 and	 gland	 foveoli	 (Figure	 33).	 All	 five	 specimens	 from	 neo-BO,	 the	
expression	of	Ki67+	cells	was	significantly	higher	in	the	middle	region	than	that	
of	the	base	of	the	gland	and	the	gland	surface	(Kruskal-Wallis	one-way	analysis	


































cells	 express	MUC5AC	and	Trefoil	 factor	1(TFF1)	 and	mucinous	 secreting	 cells	
express	 MUC6	 and	 TFF2.	 In	 neo-Barrett’s	 oesophagus;	 expression	 of	 MUC5AC	
and	 TFF1	 were	 seen	 in	 the	 upper	 part	 of	 the	 neo-BO	 glands	 with	 decreasing	
expression	towards	the	middle	region	of	neo-Barrett’s	glands	(Figure	35	and	36).	




5)	 demonstrated	 positive	 staining.	 This,	 and	 analysis	 of	 the	 H&E	 section	 from	
each	 specimen	 reveals	 that	 the	 majority	 of	 the	 neo-Barrett’s	 patients	 in	 this	








(i)	H&E	 staining	of	neo-BO;	 (ii)	MUC5AC	protein	was	mainly	 expression	 in	 the	
upper	 portion	 of	 the	 neo-Barrett’s	 gland;	 (iii)	 MUC6	 protein	 expression	 was	
mainly	seen	at	the	base	of	neo-Barrett’s	glands;	(iv)	TFF1	and	(V)	TFF2	protein	
expression	 in	 neo-BO	 were	 similar	 to	 MUC5AC	 and	 MUC6	 respectively.	 (vi)	







(i)	H&E	 staining	of	neo-BO;	 (ii)	MUC5AC	protein	was	mainly	 expression	 in	 the	
upper	portion	of	neo-Barrett’s	glands;	(iii)	MUC6	protein	expression	was	mainly	
seen	at	the	base	of	neo-Barrett’s	glands;	(iv)	TFF1	(Trefoil	family	factor)	and	(V)	








(i)	 H&E	 staining	 of	 Barrett’s;	 (ii)	 Showing	 Ki67	 expression	 within	 Barrett’s	
glands,	Ki67	positive	 cells	 are	predominantly	 situated	 in	 the	 central	portion	of	
the	gland,	similar	to	pyloric	glands;	(iii)	MUC5AC	protein	was	mainly	expression	









1)	 Neo-Barrett’s	 seems	 to	 be	 genuinely	 a	 de	 novo	 Barrett’s	 lesion,	 and	 not	 a	
recurrence	of	the	clone	that	gave	rise	to	the	OA.	






Barrett’s	oesophagus	 represents	 field	cancerisation	of	 the	oesophagus.	 It	would	
be	of	particular	concern	if	post-oesophagectomy	Barrett’s	oesophagus	contained	
the	same	founder	mutation	as	the	adenocarcinoma	and	would	suggest	that	Neo-
Barrett’s	 has	 a	 high	 risk	 of	 reforming	 OA.	 However,	 in	 the	 limited	 number	 of	
genes	sequenced,	no	shared	mutations	were	detected.	However,	data	presented	
here	has	not	shown	any	mutation	evidence	of	field	cancerization	in	this	respect,	
indicating	 that	 neo-Barrett’s	 is	 genuinely	 a	 de	 novo	 Barrett’s	 lesion	 and	 not	 a	
recurrence	 from	 the	 original	 BO.	 A	 longitudinal	 study	 looking	 at	 genotype	 of	






the	 phenotypic	 landscape,	 the	 time	 taken	 for	 the	 appearance	 of	 different	
phenotypes	 and	 to	 assess	 commonality	 between	 BO	 and	 neo-BO	 using	
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immunohistochemistry.	 They	 have	 shown	 that	 36%	 of	 neo-BO	 showed	
phenotypic	 changes	 of	 metaplasia,	 which	 is	 10%	 less	 than	 what	 has	 been	
reported	 in	 the	 past	 (Oberg	 et	 al.,	 2002,	 Dresner	 et	 al.,	 2003).	 Non-goblet	 cell	
columnar	epithelium	was	seen	earlier	than	goblet-cell	metaplasia	(median	of	4.8	
vs	8.1	years;	p=0.025)	and	62%	of	neo-BO	specimens	expressed	cytokeratin	7/20	




In	 this	 study,	 immunostaining	 of	 neo-BO	 has	 shown	 that	 the	 gene	 expression	
pattern	 of	 neo-BO	 glands	 is	 similar	 to	 that	 of	 gastric-pyloric	 glands.	 The	 upper	
part	 of	 neo-BO	 gland	 expresses	 TFF1	 and	 MUC5AC,	 whereas,	 cells	 at	 the	 base	
express	TFF2	and	MUC6	 similar	 to	 gastric-pyloric	 glands.	MUC2	was	 expressed	
mainly	in	goblet	cells	predominantly	in	the	upper	part	of	the	gland.	Ki67	+	cells	
were	 predominantly	 represented	 in	 the	 middle	 portion	 of	 neo-BO	 glands,	
suggesting	that	the	proliferative	zone	in	neo-BO	gland	is	located	at	the	center	of	
the	 gland	which	 is	 in	 the	 region	 corresponding	 to	 the	 neck/isthmus	 of	 gastric-




How	 does	 neo-barrett’s	 develop?	 The	 oesophago-gastric	 junction	 is	 always	
removed	 during	 oesophagectomy	 for	 oesophageal	 adenocarcinoma.	 Hence,	 the	
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patients	 who	 had	 BO	 (Hoffman	 et	 al.,	 2007)	 (Marshall	 et	 al.,	 1997).	 Similarly,	
studies	 in	 patients	 who	 underwent	 oesophagectomy	 for	 OA	 have	 shown	
regeneration	 of	 columnar	 epithelium	 at	 oesophagogastric	 anastomosis	 junction	
in	 12	 out	 of	 19	 patients	who	 underwent	 subtotal	 thoracic	 oesophagectomy	 for	
oesophageal	cancer,	9	of	which	had	developed	columnar	regeneration	within	four	
months	 of	 surgery	 (Hamilton	 and	 Yardley,	 1977).	 Similar	 results	 have	 been	
shown	 in	 patients	 who	 underwent	 cervical	 oesophagectomy	 	 (Lindahl	 et	 al.,	
1990).	 These	 studies	 also	 showed	 significant	 gastric	 reflux	 in	 patients	 who	
underwent	 oesophagectomy.	 Dresner	 et	 al.,	 demonstrated	 the	 development	 of	
Barrett’s	metaplasia	 in	 patients	who	 underwent	 oesophagogastric	 anastomosis.	
In	 their	 study,	 the	 columnar	 epithelium	 was	 seen	 in	 19	 out	 of	 40	 patients,	 of	
which	 10	 had	 cardiac-type	 epithelium	 and	 9	 had	 intestinal	 metaplasia.	 Seven	
patients	were	 followed	 serially	 showed	 initial	 cardiac-type	 epithelium	 followed	
by	 intestinal	 metaplasia.	 In	 patients	 with	 columnar	 metaplasia,	 there	 was	
significant	acid	and	bile	reflux	(Dresner	et	al.,	2003).	During	oesophagectomy	the	
cardiac/fundic	part	of	stomach	is	removed,	hence	the	presence	of	cardiac-type	or	
intestinal	 type	 epithelium	 at	 the	 anastomotic	 junction	 suggest	 that	 proximal	
migration	of	gastric	glands	may	not	be	the	source	of	neo-BO,	which	is	supported	




This	 raises	 the	 possibility	 of	 the	 presence	 of	multipotent	 stem	 cells	within	 the	
remnant	oesophageal	squamous	epithelium	or	oesophageal	gland	ducts.	
The	origin	of	BO	has	been	hotly	debated	(Quante	et	al.,	2012,	Xian	et	al.,	2012).	












































Our	 understanding	 of	 the	 genetic	 and	 epigenetic	 alterations	 involved	 in	 the	
development	of	Barrett’s	has	dramatically	improved	how	we	view	the	evolution	
of	 Barrett’s.	 Recently,	 Stachler	 et	 al.,	 (2015),	 using	whole	 genome	 sequencing,	
have	 constructed	 phylogenetic	 trees	 of	 Barrett’s	 epithelium	 from	
oesophagectomy	 specimens.	 They	 have	 shown	 that	 Barrett’s	 is	 made	 up	 of	
multiple	 subclones	 distributed	 throughout	 the	 tissue.	 (Stachler	 et	 al.,	 2015).	
However	the	dynamics	of	expansion	has	not	been	effectively	studied	and	there	is	
a	 need	 to	 understand	 the	 rate	 at	 which	 mutated	 glands	 divide	 through	 the	
Barrett’s	lesion	as	a	potential	risk	factor	for	cancer	progression.		It	is	established	
that	 the	 size	 of	 Barrett’s	 lesions	 remain	 static	 over	 time	 (Lim	 et	 al.,	 2010),	
therefore	clones	can	only	expand	within	a	finite	space.		Recent	evidence	suggests	
that	clonal	expansions	within	the	Barrett’s	lesion	may	occur	as	a	result	of	gland	
fission	 (Nicholson	 et	 al.,	 2012),	 which	 has	 also	 been	 previously	 shown	 in	 the	





used	SNP	arrays	 to	show	that	Barrett’s	patients	 that	do	not	progress	 to	cancer	





suggest	 that	 calculating	 the	 clonal	 expansion	 rate	within	 the	Barrett’s	 segment	
itself	may	predict	cancer	risk.	
	




sites	 in	gene	promoters	 (Ahuja	et	 al.,	 1998,	 Issa,	2000).	 It	has	been	 shown	 that	
methylation	 increases	 with	 age	 (Kim	 and	 Shibata,	 2004,	 Issa	 et	 al.,	 1994,	 Issa,	
2000)	and	 is	 inherited	during	mitosis,	hence	methylation	patterns	between	two	
cells/glands	 within	 a	 tissue	 records	 their	 ancestry	 (Holliday,	 1987).	 The	
divergence	 caused	 by	 random	 methylation	 errors	 that	 are	 acquired	 during	
mitosis	can	also	be	used	to	record	time	as	they	are	also	 inherited	by	 future	cell	
divisions	 (Kim	 and	 Shibata,	 2002).	 Methylation	 patterns	 would	 be	 similar	 in	
recently	divided	glands	that	share	a	recent	common	ancestry	and	more	diverse	in	
those	 that	 are	 more	 distantly	 related	 (Kim	 and	 Shibata,	 2004).	 Methylation	
patterns	can	also	be	used	as	a	proxy	to	reconstruct	stem	cell	phylogeny,	 if	each	




Genetic	 evolution	 studies	 have	 revealed	 clonal	 expansions,	 but	 have	 not	 yet	







logical	 to	hypothesise	 that	 rate	of	progression	 to	cancer	may	correspond	 to	 the	
clonal	expansion	rate.	 	When	we	consider	cancer	as	a	disease	of	evolution	 then	
understanding	 clonal	 expansion	dynamics	 becomes	necessary	when	 attempting	
to	 produce	 adequate	 cancer	 risk	 analysis.	 Clonal	 expansions	 are	 a	 known	 risk	
factor	 for	 oesophageal	 cancer	 progression	 (Maley	 et	 al.,	 2004a)	 and	 has	 been	
shown	to	be	the	case	in	ulcerative	colitis	(Salk	et	al.,	2009).	An	increase	in	the	rate	
of	 stem	 cell	 divisions	 and	 gland	 fission	 is	 the	 likely	 mechanism	 of	 clonal	
expansion	within	the	upper	gastrointestinal	tract	(Baker	et	al.,	2014;	McDonald	et	
al.,	 2008).	 The	 rate	 of	 fission	 is	 increased	 in	 inflammatory	 conditions	 such	 as	




We	 do	 not	 know	 the	 expansion	 dynamics	 and	 stem	 cell	 dynamics	 of	 Barrett’s	
glands	 and	 in	 this	 chapter,	 I	 attempt	 to	 investigate	 these	 using	 methylation	
patterns	 within	 the	 promoter	 regions	 of	 non-expressed	 genes	 in	 ex	 vivo	
specimens.	 This	 study	 aims	 to	 use	 methylation	 patterns	 of	 CpG	 islands	 in	 the	
promoters	of	non-expressed	genes	such	as	CSX	(cardiac-specific	homeobox	gene	
otherwise	 known	 as	NK2	 homeobox	 5	 gene)	 and	MYOD	 (member	 of	 the	 basic-
helix-loop-helix	 family	of	proteins).	Non-expressed	genes	are	used	for	the	study	









within	 CpG	 islands	 also	 increases	 (Chu	 et	 al.,	 2007).	 Errors	 in	 methylation	




molecular	 clock	 measuring	 stem	 cell	 dynamics	 (the	 methylation	 distance	
between	 cells	 within	 a	 gland)	 and	 the	 clonal	 expansion	 rate	 (the	 methylation	
distance	 between	 glands	 within	 a	 Barrett’s	 lesion).	 Each	 Barrett’s	 gland	 is	
maintained	 by	 a	 population	 of	 stem	 cells,	 and	 therefore	 the	 more	 stem	 cell	
divisions	that	occur	within	glands,	the	greater	the	intragland	methylation	pattern	












of	 binary	 ‘methylated(1)/unmethylated(0)’	 for	 each	 CpG	 site).	 Here,	 tags	 are	
sequenced	 from	 two	 different	 Barrett’s	 glands.	 It	 is	 clear	 that	 there	 is	 more	
diversity	within	the	lower	gland	than	the	upper	gland.	Intragland	analysis	shows	
increased	cell	turnover	(and	therefore	stem	cell	turnover)	in	the	lower	gland	and	





Yatabe	 et	 al.,	 (2001),	 used	 methylation	 patterns	 to	 determine	 the	 stem	 cell	




and	 also	 increased	 with	 patient	 age,	 suggesting	 that	 crypt	 stem	 cells	 are	





confident	 that	 methylation	 pattern	 diversity	 represents	 stem	 cell	 behavious	
because	the	majority	of	non-stem	cells	die	within	few	days	(Potten	and	Loeffler,	
1990,	 Heath,	 1996)	 and	 therefore	 methylation	 changes	 within	 proliferating	

















methylation	patterns	 to	become	diverse.	 Siegmund	et	al.,	 (2009a)	have	 isolated	
spatially	segregated	crypts	from	across	several	colonic	carcinomas	and	analysed	
their	 methylation	 patterns.	 Similar	 to	 normal	 colonic	 crypts,	 the	 epigenetic	
distance	 between	 the	 glands	 did	 not	 correlate	 with	 the	 spatial	 distance.	
Methylation	 patterns	 in	 each	 gland	 were	 consistent	 with	 multiple	 long-lived	
cancer	stem	cells.	They	also	suggested	that	the	tumour	growth	was	characterized	




Here,	 I	 use	 these	 techniques	 to	 determine	 the	 expansion	 rate	 of	 non-dysplastic	
Barrett’s	 glands.	 Calculating	 this	 will	 permit	 insights	 to	 the	 rate	 of	 expansion	






Clonal	 expansion	 is	 characterised	 by	 long	 periods	 of	 stasis	 and	 large	 clonal	









1)	To	use	methylation	patterns	of	non-expressed	genes	 to	establish	 the	 rate	of	
clonal	expansion	in	non-dysplastic	Barrett’s	epithelium.	






6.4.1	 Genomic	 mutation	 screening	 of	 resection	 and	 biopsy	
samples:		
Tissue	was	macro-dissected	 from	Fresh	 frozen	EMRs	 and	biopsies	 (for	 details,	
refer	 chapter-2.	 Methods-2.2)	 then	 screened	 for	 mutations	 in	 the	 variable	
regions	 of	 p16INK4A,	 TP53	 and	 KRAS	 genes.	 Specimens	 with	 an	 identified	
mutation	were	then	serially	sectioned,	and	glands	were	histologically	graded	and	
then	microdissected	 using	 a	 laser	 capture	microscope.	 Glands	were	 sequenced	




Dual	 CCO	 and	 SDH	 staining	were	 performed	 on	 fresh	 frozen	 EMRs	 to	 identify	






DNA	was	extracted	 from	 laser-captured	microdissected	glands	and	subjected	 to	
bisulphite	 treatment	 (Qiagen,	 UK).	 	 A	 nested	 PCR	 protocol	 was	 then	 used	 to	
generate	PCR	products	for	cloning.	Specific	CpG	islands	within	the	promoters	of	
MYOD1	and	CSX	were	amplified.	The	primer	was	designed	using	Primer	3	website	
(MIT,	 Cambridge,	 Massachusetts,	 USA).	 PCR	 products	 were	 subjected	 to	 TA-







(A)	 DNA	was	 extracted	 from	 10-12	white	 colonies	 and	 subjected	 to	 PCR	with	
M13	universal	primers.	 (B)	PCR	products	were	 then	 sequenced.	 	 (C)	Each	 row	
represents	methylation	tags	 from	individual	cloned	PCR	products	derived	 from	
bisulfite	treated	DNA	from	Barrett’s	gland.	Each	column	represents	CpG	site	in	a	





Methylation	patterns	 are	 converted	 to	 a	binary	 code.	Methylated	 sites	 in	 a	CpG	
island	were	represented	as	‘1’	and	unmethylated	sites	as	‘0’.	Epigenetic	diversity	

































mutations	 in	 TP53,	 CDKN2A	 and	 KRAS.	 Only	 2	 out	 of	 17	 specimens	 revealed	
mutations;	one	 sample	 showed	a	 somatic	mutation	 in	CDKN2A	 (c.329G>A)	and	
CDKN2A	 LOH.	 The	 other	 revealed	 an	mtDNA	mutation	 (9715G>A).	 In	 total	 six	
specimens	 were	 analysed,	 and	 were	 selected	 because	 they	 displayed	 well	
orientated	(full	length)	glands	(Table	7).	Mapping	of	the	mutation	status	of	each	
gland	onto	tissues	sections	did	not	reveal	multiple	clones	in	the	CDKN2A	mutant	







All	 6	 specimens	 underwent	 the	 same	 gland	 selection	 and	 bisuplhite	 protocol	
(refer	 Chapter	 2,	 Methodology	 2.10).	 Methylation	 pattern	 diversity	 was	
compared	 between	 glands	 and	 within	 glands.	 Epigenetically	 diverse	 Barrett’s	
glands	 are	 likely	 to	 represent	 distant	 clonal	 expansions.	 However,	 similar	

























3	 55	 F	 Metaplasia	 EMR	 for	
dysplasia	
None	

































The	 DNA	 from	 individual	 laser	 captured	 glands	 were	 subjected	 to	 bisulphite	
conversion	 followed	 by	 TA-cloning	 and	 sequencing	 to	 reveal	 the	 methylation	
patterns	 (8	 per	 gland)	 in	 the	 promoters	 of	 CSX	 and	 MYOD1	 (see	 Chapter	 2,	
Methodology	 2.10	 Figure	 12).	 To	 easily	 visualize	 gland	methylation	 patterns	 I	




methylation	 patterns	 for	 patient	 1	 (Figure	 40	 and	 41),	 the	 other	 patients	 are	
shown	 in	 the	appendices.	 In	patient	1,	only	gland-1	was	wild	 type	 for	CDKN2A	
and	 the	 remaining	 glands	 expressed	 a	 c.329	 G>A	 mutation.	 9	 glands	 were	


























6.5.3	 Individual	 Barrett’s	 glands	 are	 maintained	 by	 multiple	
stem	cells:	
The	 number	 of	 different	 methylation	 patterns	 (unique	 tags)	 observed	 within	
each	 gland	 were	 analysed	 across	 all	 6	 patients.	 Histologically,	 all	 glands	





and	 2.8	 for	 CSX	 and	MYOD	 respectively.	 These	 observations	 suggest	 stem	 cell	
populations	 in	Barrett’s	 glands	display	 random	stem	cell	 loss	 and	 replacement	































6.5.5	 Epigenetic	 distance	 as	 a	 measurement	 of	 recent	 clonal	
ancestry	in	Barrett’s	glands	
The	 average	 epigenetic	 distance	 between	methylation	 tags	 of	 each	 cloned	PCR	
product	reveals	diversity	(and	therefore	the	degree	to	which	each	cell	is	related	













further	 glands	 were	 away	 from	 each	 other	 the	 greater	 the	 difference	 in	 ICD	
(Figure	46).	These	observations	suggest	that	while	Barrett’s	glands	show	recent	
local	 expansions	 the	 lesion	 as	 a	 whole	 does	 not.	 The	 cumulative	 analysis	 of	
methylation	 distance	 at	 a	 CpG	 locus	within	 CSX	 and	MYOD	promoters	 in	 laser	
captured	 glands	 from	 sections	 of	 Barrett’s	 metaplasia	 from	 all	 6	 patients	 has	
been	 shown	 in	 Figure	 46.	 Statistically	 significant	 diversity	 was	 seen	 when	
























of	 adjacent	and	distant	glands	 suggesting	 that	all	 cells	 are	derived	 from	recent	
stem	 cell	 expansions.	 The	 intergland	methylation	 patterns	were	 diverse	when	












when	 compared	 to	 comparisons	of	 adjacent	 and	distant	 glands	 suggesting	 that	















respectively	 (Figure	47),	 indicating	 that	 the	adjacent	and	distant	glands	within	
individual	 Barrett’s	 lesion	 did	 not	 have	 sufficient	 time	 to	 acquire	 significant	
epigenetic	 diversity.	 This	 suggests	 that	 Barrett’s	 glands	 within	 a	 segment	 are	






that	 methylation	 patterns	 between	 paired	 glands	 were	 statistically	 not	
significant	 (p>0.05	 for	 CSX	 and	MYOD	 using	 ANOVA).	 Methylation	 patterns	 in	








































The	 percentage	 methylation	 was	 compared	 against	 intra-gland	 diversity	 to	
compare,	if	the	percentage	methylation	would	reflect	the	diversity	within	a	gland.	







There	 seems	 to	 be	 a	 negative	 correlation	 between	 the	 percentage	methylation	































There	 was	 a	 positive	 relationship	 between	 percent	 methylation	 in	 CSX	 and	
MYOD	 gene	 with	 a	 correlation	 coefficient	 =	 +0.713	 (Figure	 51),	 validating	
observations	 seen	 in	 both	 CSX	 and	MYOD	 data	 sets.	 Minor	 differences	 can	 be	












Comparing	 methylation	 patterns	 between	 two	 distant	 glands	 may	 give	 us	 the	
mitotic	age	(numbers	of	cell	division	within	glands	since	fission)	of	the	Barrett’s	
segment	 and	methylation	patterns	within	 a	 gland	provides	us	with	 the	mitotic	
age	 of	 each	 gland.	 Depending	 on	 the	 rate	 Barrett’s	 glands	 undergo	 fission	 the	
































to	 grow	 as	 long	 as	 the	 cell	 death	 is	 balanced	with	 cell	 division.	Modified	 from	
(Siegmund	et	al.,	2009a).		
	
The	methodology	 used	 to	measure	 physical	 distance	 between	 glands	 has	 been	
explained	in	Chapter	2	(2.11.5).	To	elucidate	this	relationship,	ICD	was	compared	
with	 the	 spatial	distance	between	Barrett’s	 glands	 (Figure	53).	 	The	epigenetic	
distance	 between	 two	 cells/glands	 is	 the	 number	 of	 pairwise	 differences	















(A)	 The	 spatial	 distance	 was	 compared	 against	 epigenetic	 distance.	 Spatial	
distances	 between	 glands	were	 described	 as	 a	 unit,	 which	 corresponds	 to	 the	
average	gland	diameter	(in	pixels).	The	average	ICD	of	all	pairs	of	glands	within	
the	 EMR	 specimen	 that	 fell	 within	 the	 spatial	 interval	 was	 computed.	 Each	
coloured	 line	 represents	 individual	 patient.	 There	was	 no	 correlation	 between	
















































physical	 distances.	 The	 cumulative	 correlation	 has	 been	 shown	 in	 Figure	 53B.	
There	 was	 no	 correlation	 between	 the	 epigenetic	 and	 spatial	 distance	 of	 the	
glands	 in	 CSX	 and	 MYOD	 gene.	 Methylation	 patterns	 in	 each	 gland	 were	
consistent	 with	 multiple	 (4-1000)	 long-lived	 stem	 cells.	 Barrett’s	 growth	 is	
characterised	by	rare	short-lived	clonal	expansions.	These	observations	suggest	
that	Barrett’s	growth	progression	follows	a	uniform	or	‘flat’	clonal	distribution	as	
seen	 in	 colonic	 cancer	 cells	 (Siegmund	 et	 al.,	 2009a)	 rather	 than	 a	 selective	
sweep	across	the	lesion.	
	
6.5.10	 Epigenetic	 distance	 analysis	 of	 clonal	 verus	 non-clonal	
glands:	
Dual	staining	of	cytochrome	c	oxidase	(CCO)	and	succinate	dehydrogenase	(SDH,	
a	 nuclear-encoded	mitochondrial	 enzyme)	 histochemistry	was	 performed	 (see	
Methods	2.9.1)	 to	 identify	CCO-deficient	 glands.	 Individual	 cell	 from	each	CCO-





intra-gland	 diversity	 and	 inter-gland	 diversity	 between	 clonal	 and	 non-












consists	 of	 2	 CCO	 deficient	 glands	 (gland-1	 and	 2).	 (B)	 Laser	 capture	
microdissected	 small	 cell	 areas	 of	 the	 individual	 gland	 in	 serial	 section.	 CCO	










Filled	 circle	 denotes	 the	methylation	 status	 of	 each	 CpG	 site	 (methylated)	 and	














In	clonally	 related	CCO-deficient	glands;	 the	 intragland	methylation	distance	 (a	
measure	of	diversity)	was	lower	when	compared	to	comparisons	of	adjacent	and	
distant	 glands	 in	 both	 CSX	 and	 MYOD	 promoters.	 In	 clonally	 unrelated	 CCO-
positive	 glands;	 the	 Intra-gland	methylation	 distance	 (a	 measure	 of	 diversity)	
was	lower	when	compared	to	comparisons	of	adjacent	and	distant	glands	only	in	










the	 same	 number	 of	 colonic	 crypts	 using	 case-resampling	 bootstrap	 method	
(Graham	et	al.,	2011a).	After	applying	a	 correction	 for	methylation	percentage,	
they	 found	 that	 there	 was	 no	 significant	 difference	 between	 the	 ICD’s	 of	
adenoma	and	normal	colonic	crypts	with	p<0.01	(Humphries	et	al.,	2013).		
	
The	 two	models	 constructed	 for	 estimating	 clonal	 expansion	 rate	 in	 the	 colon	
were	applied	to	Barrett’s	because	both	the	colonic	crypt	and	the	Barrett’s	gland	
expand	by	fission.	Two	assumptions	were	made	(1)	the	‘Burst’	model	assumes	all	
clonally-related	 crypts	were	 formed	 rapidly	with	no	 further	 crypt	division	 and	
(2)	 the	 ‘continual’	model	assumes	steady	growth	wherein	crypts	divide	every	 f	
years.	Epigenetic	diversity	seen	 in	colon,	 fitted	the	burst	model	better	 than	the	
continual	model,	wherein,	 sublcones	demonstrate	 a	more	 recent	 ancestry	 than	
the	adenoma	as	a	whole	(Humphries	et	al.,	2013).	This	can	be	directly	applied	to	







whisker	 plot	 below)	 and	 glands	 with	 >50%	 of	 the	 distance,	 were	 grouped	




(yellow	coloured	box	and	whisker	plot	below)	 in	 individual	Barrett’s	 specimen	
(Figure	58).	
	
The	 Inter-gland	methylation	 distance	 between	 distant	 glands	was	 lower	when	
compared	to	comparisons	of	adjacent	glands.	The	black	line	within	each	yellow	
box	and	whisker	plot	represents	the	median	and	crosses	the	burst	model	growth	








The	epigenetic	diversity	 in	 the	burst	model	 (red	 line)	 and	 the	 continual	model	
(green	line).	The	dashed	line	represents	95%	quantiles	of	the	simulated	values.	

































The	 ‘burst’	 model,	 (red	 lines)	 and	 ‘continual	 fission’	 model	 (green	 lines)	 are	
plotted.	 Interrupted	 lines	 represent	 the	 95%	 quantiles.	 The	 ICDs	 from	 all	
Barrett’s	patients	with	glands	located	less	the	average	physical	distance	between	
all	 glands	 (green	 box	 and	 whiskers)	 and	 those	 greater	 than	 50%	 of	 distance	







Epigenetic	 diversity	 between	 Barrett’s	 glands	 was	 simulated	 with	 a	












Phylogenetic	 trees	 were	 created	 to	 understand	 the	 evolutionary	 history	 of	
Barrett’s	glands	from	single	specimens	using	methylation	data	to	give	an	insight	
into	 the	 degree	 of	 ancestry	 between	 glands	 in	 this	 study.	 Phylogeny	was	 built	
using	 a	 neighbour-joining	 (nj)	 method	 using	 the	 analysis	 of	 phylogenetics	 and	
evolution	(ape)	package	in	the	R	statistical	computing	programme	(Paradis	et	al.,	
2004).	Each	 leaf	represents	an	 individual	Barrett’s	gland	(length	of	 the	 tip	does	
corresponds	 to	 its	 relative	mitotic	age)	 (Figure	60).	These	observations	suggest	
Barrett’s	glands	do	not	follow	a	linear	pathway	of	progression.	Widely	separated	
























































































































































































































































There	 was	 a	 trend	 towards	 a	 rising	 number	 of	 unique	 tags	 with	 age	 but	 was	
statistically	not	significant.	The	number	of	unique	patterns/tags	observed	within	
a	gland	reflects	stem	cell	numbers.	Methylation	patterns	within	a	gland	observed	
in	 this	 study	 were	 variable	 and	 each	 gland	 showed	 at	 least	 3	 to	 4	 different	






	Methylation	 tags	 sampled	 from	 a	 Barrett’s	 gland.	 Each	 row	 represents	
methylation	 tags	 from	 individual	 cloned	 PCR	 products	 and	 each	 column	
represents	 CpG	 site	 in	 a	 CpG	 island.	 Methylated	 site	 in	 a	 CpG	 island	 are	
designated	 as	 ‘1’	 and	 unmethylated	 site	 as	 ‘0’.	 The	 number	 of	 unique	
patterns/tags	observed	within	a	gland	reflects	stem	cell	numbers	(4	stem	cells	in	







to	 adjacent	 or	 distant	 glands,	which	 in	 turn	were	 comparatively	more	 diverse	
(Figure	62).	Barrett’s	stem	cells	 follow	niche	model	with	random	stem	cell	 loss	
and	 replacement	 leading	 to	 niche	 succession,	 which	 counteracts	 further	
methylation	 changes,	 leading	 to	 relatively	 less	 diverse	 methylation	 patterns	
within	 a	 gland.	 The	 populated	 cells	 within	 a	 Barrett’s	 gland	 appeared	 to	 be	
mitotically	recent	compared	to	the	rest	of	the	Barrett’s	lesion.	Our	data	suggests	













There	 was	 no	 correlation	 between	 the	 epigenetic	 and	 spatial	 distance	 of	 the	
glands	 in	 all	 six	 specimens	 analysed,	 suggesting	 that	 epigenetic	 diversity	 is	
independent	 of	 the	 spatial	 distance	 between	 Barrett’s	 glands	 (Figure	 63).	
Barrett’s	 follows	 start-shaped	 phylogeny	 wherein	 the	 methylation	 patterns	





The	 physical	 distance	 between	 Barrett’s	 glands	 did	 not	 correlate	 with	 their	
intergland	epigenetic	distance.	
	
4)	 Barrett’s	 oesophagus	 shows	 the	 flat	 clonal	 progression:	 There	 was	 no	
correlation	between	the	epigenetic	and	spatial	distance	of	the	glands	in	CSX	and	
MYOD	gene.	The	methylation	patterns	within	adjacent	glands	were	as	unrelated	





The	 methylation	 patterns	 between	 adjacent	 clonal	 glands	 with	 same	 CDKN2A	





Methylation	 patterns	 between	 clonal	 glands	 (Blue	 circles)	 were	 as	 diverse	 as	












Our	 knowledge	 about	 Barrett’s	 oesophagus	 lacks	 information	 regarding	
progression	 of	 Barrett’s	 lesion.	 It	 is	 also	 difficult	 to	 predict	 how	 and	when	 an	
individual	 develops	 Barrett’s	 lesion.	 Most	 human	 models	 towards	 Barrett’s	
progression	 are	 based	 on	 inferences,	 as	 it's	 hard	 to	 observe	 the	 growth	 of	




size	 of	 Barrett’s	 lesion	 should	 correspond	 to	 its	 age.	 The	 ‘molecular	 clock’	
hypothesis	 suggests	 that	 the	 greater	 the	 number	 of	 divisions	 since	 a	 common	
ancestor,	the	greater	the	number	of	differences	(Bromham	and	Penny,	2003).	If	
Barrett’s	 lesion	 expands	 through	 sequential	 step-wise	 clonal	 expansions,	 then	
the	newer	population	of	cells	should	be	more	diverse	than	the	older	population	
of	 cells.	 However,	 if	 the	 lesion	 develops	 to	 it	 full	 extent	 and	 subsequently	
becomes	 stable,	 then	 the	population	of	 cells/glands	 should	be	 less	diverse	and	
should	be	of	similar	age.	 In	 this	study,	 it	has	been	shown	that	Barrett’s	 follows	
‘burst’	 model	 growth	 causing	 cell	 lineages	 to	 be	 created	 early	 in	 progression	
followed	by	a	stable/flat	growth.	
	
Epigenetic	 alterations	 such	 as	 promoter	 methylation	 in	 non-expressed	 genes	





crypts	 are	 long-lived	 and	 contain	 multiple	 stem	 cells.	 	 Methylation	 patterns	
within	a	crypt	show	that	these	stem	cells	undergo	constant	bottlenecks	and	two	
continuous	counteracting	but	invisible	forces	namely	drift	(difficult	to	document	
as	 mutations	 in	 normal	 human	 tissue	 are	 rare	 (Martin	 et	 al.,	 1996))	 and	









this	 study,	 the	 methylation	 patterns	 between	 clonally	 related	 adjacent	 glands	
were	different,	 suggesting	 that	 epigenetic	 diversity	 is	 independent	 of	 clonality.	
Adjacent	glands	were	more	closely	related	than	a	distant	gland.	Furthermore,	the	
physical	 distance	 between	 Barrett’s	 glands	 did	 not	 correlate	 with	 their	
epigenetic	distance.	These	observations	suggest	gland	fission	was	a	slow	process	
allowing	 sufficient	 time	 for	 two	 daughter	 glands	 to	 become	 epigenetically	
diverse.		
	
In	 Colon,	 it	 has	 been	 shown	 that	 CCO-deficient	 patch	 increases	 in	 size	 by	 the	
process	of	crypt	fission	and	the	patch	size	increases	with	age	(Taylor	et	al.,	2003,	




intestinal	crypts,	Kozar	et	al.,	 (2013),	have	shown	that	there	are	at	 least	 five	to	
seven	functional	stem	cells	in	healthy	intestinal	crypts	when	compared	to	nine	in	
adenomas,	 of	 which	 majority	 are	 involved	 in	 replacing	 stem	 cell	 loss	 and	 a	
minority	 of	 stem	 cells	 are	 responsible	 for	 tumour	 growth	 (Kozar	 et	 al.,	 2013).	
Recently,	to	understand	the	clonal	evolution	of	stem	cell	populations	within	the	




seems	 to	 increase	 the	 crypt	 fission	 rate	 and	 there	 was	 an	 increase	 in	 the	
functional	 stem	 cell	 number	 within	 APC	 mutated	 crypts,	 indicating	 its	
importance	 in	 tumour	 growth.	 However,	 the	 data	 here	 was	 insufficient	 to	
calculate	 any	 patch	 size.	 Despite	 Barrett’s	 glands	 being	 clonal	 for	 the	 somatic	
genomic	 mutation	 (patient	 1)	 and	 mtDNA	 mutation	 (paient	 2),	 the	 Barrett’s	
glands	contained	multiple	unique	patterns,	suggesting	that	each	gland	contained	
multiple	 long-lived	 stem	cells	 (Baker	 et	 al.,	 2014).	Methylation	patterns	within	
clonal	Barrett’s	glands	had	various	patterns	suggesting,	niche	succession	was	a	





the	 difference	 in	 the	 number	 of	 CpG	 sites	 (CSX	 has	 8	 CpG	 sites	 compared	 to	
MYOD,	 which	 has	 five)	 and	 due	 to	 the	 differences	 in	 site-specific	 methylation	
rates.	 Increasing	 the	 number	 of	 CpG	 sites	 does	 not	 necessarily	 improve	 the	
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accuracy	 of	 results	 as	 methylation	 is	 acquired	 randomly	 leading	 to	 epigenetic	
drift,	which	increases	by	increasing	the	number	of	CpG	sites	(Yatabe	et	al.,	2001).		
The	 average	 methylation	 pattern	 diversity	 within	 different	 clones	 is	 a	 better	
measure	of	diversity	(Graham	et	al.,	2011a).	
	
The	 time	 scale	 from	 Barrett's	 to	 OA	 is	 unclear.	 In	 a	 case	 report,	 a	 long-term	
follow--up	of	a	patient	with	Barrett's	over	a	period	of	15	years	has	shown	that	it	
took	nearly	nine	years	for	a	patient	to	progress	from	short	segment	BO	to	 long	
segment	 BO	 and	 further	 to	 OA	 (Iwaya	 et	 al.,	 2016).	 During	 its	 progression	
through	 MDC	 sequence,	 Barrett’s	 glands	 are	 exposed	 to	 various	 evolutionary	
selective	forces.	If	specific	somatic	genomic/mtDNA	mutations	confer	a	selective	
advantage	 to	 a	 gland	 (or	 clone),	 then	 that	 clone	 would	 expand	 rapidly	 and	
methylation	 patterns	 would	 be	 homogenous	 due	 to	 not	 enough	 time	 having	
passed	 for	 them	 to	 have	 become	 drivers.	 The	 high	 epigenetic	 diversity	 seen	
within	clonally	related	BO	glands	suggests	only	weak	selection	for	that	particular	
clone.	 Methylation	 pattern	 data	 analysis	 in	 BO	 has	 suggested,	 that	 Barrett's	
glands	 comprised	 of	 a	 more	 recent	 common	 ancestor	 when	 compared	 to	 the	
whole	 Barrett's	 segment.	 In	 other	 words,	 the	 Barrett's	 segment	 consists	 of	

























Cancer	 genomic	 studies	 have	 revealed	 significant	 intra-tumour	 heterogeneity	
(ITH)	with	branching	phylogenies	(Siegmund	et	al.,	2009b,	Sottoriva	et	al.,	2013).	
However,	 the	 origins	 of	 genetic	 heterogeneity	 are	 unknown.	 Tumorigenesis	 is	
always	 thought	 to	be	 secondary	 to	 stepwise	accumulation	of	driver	 alterations	
(Fearon	 and	Vogelstein,	 1990)	 and	 is	 a	 dynamic	 process;	 the	 ancestral	 history	
gets	recorded	within	 the	cell	genomes	(Greaves	and	Maley,	2012,	Vogelstein	et	
al.,	2013).	In	the	absence	of	selective	sweep,	information	regarding	early	growth	
phase	 may	 be	 recorded	 within	 genomes	 giving	 rise	 to	 genetic	 heterogeneity,	
which	becomes	evident	in	the	final	lesion.	The	heterogeneity	could	be	due	to	the	
presence	of	multiple	sub-clonal/private	alterations,	most	of	which	are	said	to	be	
non-dominant	 (passenger	mutations/alterations)	 and	 can	 be	 detected	 through	
systematic	 sampling	 and	 genomic	 profiling	 of	 various	 regions	 within	 a	 lesion	




or	 if	 there	 are	 distinct	 groups	 of	 glands	 forming	 multiple	 clones.	 The	
development	of	oesophageal	cancer	involves	genetic	changes	and	mutations	are	
known	 to	 accumulate	 in	 Barrett’s	 glands	 as	 they	 go	 through	 the	 metaplasia-
dysplasia-carcinoma	sequence	(MDC).	Earlier	studies	 into	the	genetic	evolution	





genetically	 heterotypic	 disease.	 Furthermore,	 Maley	 et	 al.,	 have	 shown	 that	












3)	 The	 presence	 of	 a	 TP53,	 CDKN2A	 (p16)	 and	 KRAS	 mutation	 in	 associated	
cancer	 suggests	 that	 the	mutated	 clone,	 but	not	 the	wild-type	dysplastic	 clone,	
progressed	to	cancer.	
4)	 Oesophageal	 carcinomas	 are	 monoclonal	 outgrowths	 from	 polyclonal	
dysplasia.	






6)	 Heavy	 mutational	 burdens	 in	 critical	 tumour	 suppressor	 genes	 can	 be	
associated	with	apparently	normal	gland	organisation	and	certainly	without	the	
appearances	of	dysplasia.	




8a)	 Barrett’s	 gland	 is	 maintained	 by	 more	 than	 one	 long-lived	 stem	 cell.	 The	
number	 of	 unique	 tags	 in	 Barrett’s	 glands	 increased	 with	 age	 and	 the	
methylation	patterns	within	individual	glands	were	diverse.	
8b)	Epigenetic	diversity	in	Barrett’s	metaplasia:	the	methylation	patterns	within	
a	 gland	 (ACD)	was	 less	 diverse	when	 compared	 to	 adjacent	 or	 distant	 glands,	
which	were	comparatively	more	diverse.	
8c)	Cells	within	a	Barrett’s	gland	appeared	to	be	mitotically	recent	compared	to	
the	 rest	 of	 the	 Barrett’s	 lesion.	 Our	 data	 suggests	 that	 the	 growth	 of	 Barrett’s	
metaplasia	is	slow	allowing	sufficient	time	for	the	adjacent	and	distant	glands	to	
acquire	epigenetic	diversity.	











8g)	 The	 time	 since	 Barrett’s	 glands	were	 derived	 from	 a	 single	 (transformed)	
ancestral	gland	was	at	least	four	years	and	averages	around	14	to	15	years.	
	 	
In	 Chapter	 -	 3,	 using	 targeted	 somatic	 genomic	 mutational	 status	 of	 Barrett’s	
glands,	 I	 have	 shown	 that	 Barrett’s	metaplasia	 and	 dysplasia	 arise	 from	more	
than	one	clone	suggesting	polyclonality,	whereas,	oesophageal	adenocarcinoma	





clones	 exist	 within	 Barrett’s	 oesophagus	 (Leedham	 et	 al.,	 2008).	 Here,	 I	 have	
shown	 that	 only	 one	 clone	 progresses	 to	 carcinoma	 and,	 therefore,	 Barrett’s	
adenocarcinomas	are	monoclonal.	These	observations	suggest	clonal	interaction	





in	 phenotype	 could	 be	 due	 to	mutations	 in	 other	 genes	 or	 other	 exons	 of	 the	








intestine	 (Gutierrez-Gonzalez	 et	 al.,	 2009),	 gastric	 mucosa	 (McDonald	 et	 al.,	
2008)	 and	 indeed	 in	 gastric	 intestinal	 metaplasia	 (Gutierrez-Gonzalez	 et	 al.,	
2009)	 patches	 of	 clonally-identical	 crypts	 are	 seen,	 strongly	 suggesting	 that	
crypt	 or	 gland	 fission	 is	 the	 process	 underlying	 this	 expansion.	 	 Recently,	
Barrett’s	glands	have	been	shown	to	be	clonal	populations	and	Barrett’s	mucosa	
contains	large	groups	of	clonally-identical	glands	(Nicholson	et	al.,	2011),	and	it	
appears	 probable	 that	mutant	 clones	 involved	 in	 the	 development	 of	 Barrett's	
dysplasia	 also	 clonally	 expand	 via	 gland	 fission,	 probably	 with	 a	 growth	
advantage	 conferred	 by	 the	 p16	 or	 TP53	 mutation.	 On	 the	 other	 hand,	
immediately	 adjacent	 glands	may	 not	 be	 derived	 from	 the	 same	 clone	 (Rhiner	
and	 Moreno,	 2009).	 There	 is	 no	 evidence	 that	 Barrett’s	 segments	 increase	 in	
length	 with	 time	 (Gatenby	 et	 al.,	 2007).	 	 Martens	 and	 colleagues	 have	 drawn	
attention	 to	 the	 fact	 that	 many	 pre-cancerous	 tissues	 have	 a	 distinct	 spatial	





explain	 the	 long	prodromal	period	 seen	before	 invasion	occurs	 in	pre-invasive	
lesions	such	as	Barrett’s	(Spechler,	2003),	inflammatory	bowel	disease	(Jess	et	al.,	





for	 clonal	 interference	 to	 occur,	 would	 appear	 to	 underline	 the	 potential	 for	




like	 atypia	 (BCDA)	 is	 associated	 with	 either	 synchronous	 or	 metachronous	
dysplasia	 or	 OA	 elsewhere	 in	 the	 oesophagus	 (Lomo	 et	 al.,	 2006,	 Coco	 et	 al.,	





as	 a	 result	 of	 a	 single	 APC	mutation	 in	 FAP	 adenomas	 (Lamlum	 et	 al.,	 2000);	
conversely,	 non-dysplastic	 tissue	 can	 also	 carry	 substantial	mutational	 burden	
(Leedham	et	al.,	2009).	These	observations	suggest	that	mutation	on	its	own	or	





high-risk	 group	 of	 developing	 OA.	 Saadi	 et	 al.,	 have	 shown	 that	 different	
phenotypes,	such	as	metaplasia,	dysplasia	and	OA	can	be	distinguish	based	on	a	








of	 field	 cancerization,	 indicating	 that	 neo-Barrett’s	 is	 genuinely	 a	 de	 novo	
Barrett’s	lesion	and	not	a	recurrence	from	the	original	BO.	Mutations	found	in	OA	
were	not	found	in	neo-Barrett	from	same	patient	suggesting	that	the	new	lesion	








have	shown	 that	Barret’s	glands	are	clonal,	 giving	rise	 to	multiple	cell	 lineages	




developed	 from	 gastric	 glands,	 which	 had	 expressed	 TFF1+/MUC5AC+	 and	








glands	 were	 not	 same,	 suggesting	 epigenetic	 diversity	 within	 Barrett’s	
oesophagus,	similar	to	methylation	patterns	 in	the	colon	(Graham	et	al.,	2011a,	
Yatabe	 et	 al.,	 2001).	 It	 has	 been	 shown	 that	 neonatal	 intestinal	 crypts	 are	
polyclonal	 to	 start	 with	 and	 by	 day	 14	 these	 crypts	 undergo	 monoclonal	
conversion	(Schmidt	et	al.,	1988).	Methylation	patterns	are	acquired	as	somatic	
inheritance	and	act	like	a	molecular	clock	(Tsao	et	al.,	2000,	Holliday	and	Pugh,	
1975).	 During	 adult	 life,	 methylation	 patterns	 undergo	 drift	 to	 become	 more	
diverse	and	polymorphic.	This	diversity	has	been	shown	in	normal	tissue	(Zhu	et	
al.,	 1999)	 and	 tumours	 such	 as	 colonic	 carcinomas	 (Sakurazawa	 et	 al.,	 2000),	
leiomyoma	(Silva	et	al.,	1993)	and	breast	carcinoma	(Graff	et	al.,	2000).	 In	 this	
study,	 it	 has	 been	 shown	 that	 an	 individual	 Barrett’s	 gland	 consists	 of	 various	
methylation	patterns	suggesting	the	presence	of	multiple	stem	cells,	which	may	
undergo	 bottleneck	 competition.	 Stem	 cell	 plasticity	 may	 be	 responsible	 for	
differences	 in	methylation	 patterns	 between	 Barrett’s	 glands.	 The	methylation	
tags	 within	 Barrett’s	 glands	 increased	 with	 age	 and	 so	 did	 the	 percentage	
methylation,	 similar	 to	 the	 colon	 (Yatabe	 et	 al.,	 2001).	 Nicholson	 et	 al.,	 have	
shown	that	Barrett’s	glands	are	maintained	by	multiple	stem	cells	(Nicholson	et	
al.,	2011).	Methylation	patterns	within	clonal	Barrett’s	glands	(clonal	mutation	in	











acquire	 diverse	methylation	 patterns.	 These	 changes	 can	 be	 explained	 by	 two	
dynamic	processes,	which	are	working	against	each	other	towards	building	the	
gland	 architecture,	 such	 as,	 stem	 cell	 extinction	 and	 drift.	 	 In	 the	 specimens	












(p16)	 have	 been	 primarily	 studied	 here.	 Not	 all	 DNA	 extractions	 yield	 DNA	 of	
sufficient	 quality	 to	 perform	 nested	 PCR	 sequencing,	 limiting	 the	 number	 of	
informative	clones	fully	 investigated.	Limited	tissue	available	 for	EMRs	raises	a	







• It	could	help	 in	the	development	of	 the	biomarkers	 for	 the	prediction	of	

















































































































































































































































































































































































































































































































































































































































































































































































































































































Table	 9	 and	 Table	 10	 highlights	 the	 number	 of	 cycles	 done,	 various	 stages	










































































































1	 Final	extension	 72	 8	








































1	 Final	extension	 60	 	


































































































































































































different	 glands	 were	 laser	 captured	 from	 the	 specimen.	 17	 out	 of	 18	 glands	
were	mutated	for	CDKN2A	(c.329G>A)	and	also	showed	CDKN2A	LOH	(Appendix,	
Table	 21),	 but	 one	 gland	 was	 wild	 type	 for	 the	 same	 mutation	 (Figure	 66),	
suggesting	 at	 least	 two	 clones	 in	 Barrett’s	 metaplasia.	 Although	 only	 a	 single	








	H&E	 of	 an	 EMR	 from	 patient	 3	 (Top	 half).	 Two-dimensional	 map	 of	 an	 EMR	
showing	 the	mutational	 status	of	 individual	 laser	captured	glands	with	cellular	
























































mutational	 status	 of	 individual	 crypts	 from	 patient	 2	 in	 Table	 3	 have	 been	
summarized	 in	 Table	 18.	 The	 spatial	 distribution	 of	 different	 phenotype	 and	
genotype	with	 their	 LOH	 status	 from	patient	 2	 in	Table	3	have	been	 shown	 in	










1	 Metaplasia	 WT	 No	LOH	
2	 Metaplasia	 WT	 No	LOH	
3	 Metaplasia	 WT	 No	LOH	
4	 Metaplasia	 WT	 No	LOH	
5	 Metaplasia	 WT	 No	LOH	
6	 Metaplasia	 WT	 LOH	
7	 Metaplasia	 WT	 LOH	
8	 Metaplasia	 WT	 LOH	
9	 Metaplasia	 WT	 No	LOH	
10	 Metaplasia	 Mutated		 LOH	
11	 Metaplasia	 Mutated	 LOH	
12	 Dysplasia	 WT		 No	LOH	
13	 Dysplasia	 WT	 No	LOH	
14	 Dysplasia	 WT	 LOH	
15	 Dysplasia	 WT	 LOH	
16	 Dysplasia	 Mutated	 LOH	









18	 Dysplasia	 Mutated	 LOH	
19	 Dysplasia	 Mutated	 LOH	
20	 Dysplasia	 Mutated	 LOH	
21	 Dysplasia	 Mutated	 LOH	
22	 Dysplasia	 Mutated	 LOH	
23	 Dysplasia	 Mutated	 LOH	
24	 Dysplasia	 Mutated	 LOH	
25	 Dysplasia	 Mutated	 Not	worked	
26	 Dysplasia	 Mutated	 Not	worked	
27	 Dysplasia	 Mutated	 LOH	
28	 Dysplasia	 Mutated	 LOH	
29	 Oesophageal	duct	 WT	 No	LOH	
30	 Carcinoma	x	4	areas	 Mutated	 LOH	
Table	20:	Correlation	between	phenotype	and	genotype	results	for	patient	
2.		
Multiplex	 PCR	 was	 performed	 with	 a	 panel	 of	 microsatellite	 markers	 located	
within	 TP53	 (17q)	 SMAD4	 (18q)	 and	 CDKN2A	 gene.	 For	 each	 marker,	 loss	 of	
heterozygosity	was	 considered	 to	be	present	 if	 the	area	under	one	allelic	peak	
was	 less	 than	0.5	 times	or	more	 than	 two	 times	 the	area	of	 the	 corresponding	




The	 constitutional	 DNA	 was	 only	 informative	 for	 CDKN2A.	 These	 glands	 were	
then	screened	for	LOH	at	CDKN2A	using	a	panel	of	microsatellite	markers	(shown	
in	Table	21).	All	 glands,	which	were	mutated	 for	CDKN2A	 showed	LOH	on	 four	
microsatellite	markers	 for	CDKN2A.	 The	 LOH	 analysis	 of	 one	 gland,	which	was	


















1	 WT	 N/W	 N/W	 N/W	 N/W	
2	 Mutated	 N/W	 LOH	 LOH	 LOH	
3	 Mutated	 LOH	 LOH	 LOH	 LOH	
4	 Mutated	 LOH	 LOH	 LOH	 LOH	
5	 Mutated	 LOH	 LOH	 LOH	 LOH	
6	 Mutated	 LOH	 LOH	 LOH	 LOH	
7	 Mutated	 LOH	 LOH	 LOH	 LOH	
8	 Mutated	 LOH	 LOH	 LOH	 LOH	
9	 Mutated	 LOH	 No	LOH	 No	LOH	 LOH	
10	 Mutated	 LOH	 LOH	 LOH	 LOH	
11	 Mutated	 LOH	 No	LOH	 No	LOH	 LOH	
12	 Mutated	 LOH	 LOH	 LOH	 LOH	
13	 Mutated	 LOH	 No	LOH	 No	LOH	 LOH	
14	 Mutated	 LOH	 LOH	 LOH	 LOH	
15	 Mutated	 LOH	 LOH	 LOH	 LOH	
16	 Mutated	 LOH	 LOH	 LOH	 LOH	
17	 Mutated	 LOH	 LOH	 LOH	 LOH	
18	 Mutated	 LOH	 LOH	 No	LOH	 LOH	
Table	21:	Summary	of	LOH	results	for	patient	3.	
Multiplex	 PCR	 was	 performed	 with	 a	 panel	 of	 microsatellite	 markers	 located	
within	 	TP53	 (17q),	 SMAD4	 (18q)	 and	 CDKN2A	 gene.	 For	 each	marker,	 loss	 of	
heterozygosity	was	 considered	 to	 be	 present	 if	 the	 area	 under	 one	 allelic	 peak	









The	 constitutional	DNA	was	 only	 informative	 for	 two	microsatellite	markers	 of	
TP53	 (D17S250	and	D17S1832).	 Laser	 captured	glands	were	 then	 screened	 for	
LOH	at	TP53	 using	 a	 panel	 of	microsatellite	markers.	 Two	out	 of	 9	metaplastic	
glands	showed	LOH	for	TP53	microsatellite	marker	(D17S1832).	All	8	dysplastic	
glands	which	were	mutated	for	TP53	(c.256	G>A),	also	showed	LOH	for	TP53	of	at	
least	one	microsatellite	marker	and	all	 eight	areas	of	 cancer	had	LOH	 for	TP53.	
Summary	of	LOH	status	is	given	in	table	22.	Here,	TP53	mutated	clone	with	TP53	
LOH	must	have	occurred	first	followed	by	the	TP53-KRAS	double	mutated	clone.	













1	 Metaplasia	 -	 WT	 WT	
2	 Metaplasia	 -	 WT	 WT	
3	 Metaplasia	 -	 WT	 WT	
4	 Metaplasia	 -	 WT	 WT	
5	 Metaplasia	 -	 WT	 WT	
6	 Metaplasia	 -	 WT	 WT	
7	 Metaplasia	 -	 WT	 WT	
8	 Metaplasia	 +	 WT	 WT	
9	 Metaplasia	 +	 Mutated	 WT	
10	 Dysplasia	 +	 Mutated	 WT	
11	 Dysplasia	 +	 Mutated	 WT	
12	 Dysplasia	 +	 Mutated	 WT	
13	 Dysplasia	 +	 Mutated	 WT	
14	 Dysplasia	 +	 Mutated	 Mutated	
15	 Dysplasia	 +	 Mutated	 Mutated	
16	 Dysplasia	 +	 Mutated	 Mutated	












Standard	 DNA	 (muscle	 area)	 was	 laser	 capture	 for	 LOH	 analysis.	 DNA	 was	
informative	for	two	microsatellite	markers	for	TP53	(D17S1176	and	D17S1881).	
Due	 to	 lack	 of	DNA,	 only	 13	 glands	 out	 of	 29	were	 analysed.	 The	 results	 have	
been	 shown	 in	 the	 table	 23	 below.	 	 The	 spatial	 distribution	 of	 different	








1	 N/W	 No	LOH	 No	LOH	
2	 WT	 No	LOH	 No	LOH	
3	 WT	 Not	amplified	 LOH	
4	 WT	 Not	amplified	 LOH	
5	 Mutated	 LOH	 LOH	
6	 Mutated	 Not	amplified	 LOH	
7	 Mutated	 Not	amplified	 	LOH	
8	 Mutated	 LOH	 LOH	
9	 Mutated	 LOH	 LOH	
10	 Mutated	 Not	amplified	 LOH	
11	 Mutated	 LOH	 LOH	
12	 Mutated	 Not	amplified	 LOH	
13	 Mutated	 LOH	 LOH	
Table	23:	Summary	of	LOH	results	for	patient	8.		
Multiplex	 PCR	 was	 performed	 for	 a	 panel	 of	 microsatellite	 markers	 located	
within	 TP53	 (17q),	 SMAD4	 (18q)	 and	 CDKN2A	 gene.	 For	 each	marker,	 loss	 of	
heterozygosity	was	 considered	 to	be	present	 if	 the	area	under	one	allelic	peak	
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was	 less	 than	0.5	 times	or	more	 than	 two	 times	 the	area	of	 the	 corresponding	






























Methylation	 patterns	 from	 gland	 1-15	 in	 CSX	 promoters.	 Each	 box	 represents	
methylation	patterns	 of	 individual	 gland;	 each	 row	 represents	 a	 tag	 (molecule)	
and	 each	 column	 represents	 a	 CpG	 site.	 The	methylation	 status	 of	 each	 CpG	 is	
represented	by	circle,	filled	circle	denotes	methylated	CpG	site	and	unfilled	circle	













methylation	patterns	 of	 individual	 gland;	 each	 row	 represents	 a	 tag	 (molecule)	
and	 each	 column	 represents	 a	 CpG	 site.	 The	methylation	 status	 of	 each	 CpG	 is	
represented	by	circle,	filled	circle	denotes	methylated	CpG	site	and	unfilled	circle	













Methylation	 patterns	 from	 gland	 1-10	 in	 CSX	 and	 MYOD	 promoters.	 Each	 box	

















Methylation	 patterns	 from	 gland	 1-9	 in	 CSX	 and	 MYOD	 promoters.	 Each	 box	



























8.6	 Correlation	 between	 epigenetic	 diversity	 and	 spatial	
distance	for	CSX	and	MYOD	gene	(individual	patient):	








































































































the	 average	 gland	 diameter	 (in	 pixels).	 The	 average	 ICD	 of	 all	 pairs	 of	 glands	
within	 the	EMR	specimen	that	 fell	within	 the	spatial	 interval	was	computed.	 In	
CSX	 and	 MYOD	 promoters,	 there	 was	 no	 correlation	 between	 spatial	 distance	
and	epigenetic	distance.	The	straight	line	indicates	that	spatially	closely	related	
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